<SEC-DOCUMENT>0001193125-23-301190.txt : 20231221
<SEC-HEADER>0001193125-23-301190.hdr.sgml : 20231221
<ACCEPTANCE-DATETIME>20231221160931
ACCESSION NUMBER:		0001193125-23-301190
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20231220
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231221
DATE AS OF CHANGE:		20231221

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Annexon, Inc.
		CENTRAL INDEX KEY:			0001528115
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				275414423
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39402
		FILM NUMBER:		231505395

	BUSINESS ADDRESS:	
		STREET 1:		1400 SIERRA POINT PARKWAY
		STREET 2:		BLDG C, SUITE 200
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
		BUSINESS PHONE:		(650)-822-5500

	MAIL ADDRESS:	
		STREET 1:		1400 SIERRA POINT PARKWAY
		STREET 2:		BLDG C, SUITE 200
		CITY:			BRISBANE
		STATE:			CA
		ZIP:			94005
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d456025d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:annx="http://annexonbio.com/20231220" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-12-20_to_2023-12-20">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-12-20_to_2023-12-20">0001528115</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="annx-20231220.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-12-20_to_2023-12-20"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001528115</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-12-20</xbrli:startDate> <xbrli:endDate>2023-12-20</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-12-20_to_2023-12-20">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 OR 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of The Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-12-20_to_2023-12-20" format="ixt:datemonthdayyearen">December 20, 2023</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2023-12-20_to_2023-12-20">ANNEXON, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-12-20_to_2023-12-20" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-12-20_to_2023-12-20">001-39402</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-12-20_to_2023-12-20">27-5414423</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(State or other jurisdiction</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">of incorporation)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Commission</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">File Number)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(IRS Employer</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Identification No.)</p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-12-20_to_2023-12-20">1400 Sierra Point Parkway</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2023-12-20_to_2023-12-20">Bldg C</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine3" contextRef="duration_2023-12-20_to_2023-12-20">Suite 200</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-12-20_to_2023-12-20">Brisbane</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-12-20_to_2023-12-20" format="ixt-sec:stateprovnameen">California</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-12-20_to_2023-12-20">94005</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices) (Zip Code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Registrant&#8217;s telephone number, including area code: <ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-12-20_to_2023-12-20">(650)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-12-20_to_2023-12-20">822-5500</ix:nonNumeric></span></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former name or former address, if changed since last report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-12-20_to_2023-12-20" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-12-20_to_2023-12-20" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-12-20_to_2023-12-20" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-12-20_to_2023-12-20" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-12-20_to_2023-12-20">Common Stock, par value $0.001 per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-12-20_to_2023-12-20">ANNX</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-12-20_to_2023-12-20" format="ixt-sec:exchnameen">The Nasdaq Stock Market</ix:nonNumeric></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">Emerging growth company&#160;&#160;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-12-20_to_2023-12-20" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#160;&#160;&#9744;</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;1.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December 20, 2023, Annexon, Inc. (the &#8220;C<span style="font-weight:bold"><span style="font-style:italic">ompan</span></span>y&#8217;) entered into an underwriting agreement (&#8220;<span style="font-weight:bold"><span style="font-style:italic">Underwriting Agreement</span></span>&#8221;) with Jefferies LLC and Cowen and Company, LLC (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Underwriters</span></span>&#8221;), to issue and sell 25,035,000 shares (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Shares</span></span>&#8221;) of the Company&#8217;s common stock, par value $0.001 per share (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Common Stock</span></span>&#8221;) at a price of $2.880 per share and, in lieu of Common Stock, certain investors were <span style="white-space:nowrap">issued&#160;pre-funded&#160;warrants</span> to purchase an aggregate of 18,379,861 shares of Common Stock at a price of $2.879 (the&#160;&#8220;<span style="font-weight:bold"><span style="font-style:italic"><span style="white-space:nowrap">Pre-Funded</span></span></span><span style="font-weight:bold"><span style="font-style:italic"></span></span><span style="font-weight:bold"><span style="font-style:italic">&#160;Warrants</span></span>&#8221;), which represents the per share price for the Shares less the $0.001 per share exercise price for <span style="white-space:nowrap">each&#160;Pre-Funded&#160;Warrant</span> (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Offering</span></span>&#8221;). The gross proceeds from the Offering are expected to be approximately $125.0&#160;million before deducting underwriting commissions and discounts and offering expenses. All of the Shares and the <span style="white-space:nowrap">Pre-Funded</span> Warrants are being sold by the Company. The Offering is expected to close on December 26, 2023, subject to customary closing conditions. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities described above are offered and will be issued pursuant to a shelf registration statement on Form <span style="white-space:nowrap">S-3</span> (File&#160;No. <span style="white-space:nowrap">333-258863)</span> and the related prospectus and prospectus supplement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="white-space:nowrap">The&#160;Pre-Funded&#160;Warrants</span> will be exercisable at any time after the date of issuance. A holder <span style="white-space:nowrap">of&#160;Pre-Funded&#160;Warrants</span> may not exercise the warrant if the holder, together with its affiliates, would beneficially own more than 9.99% of the number of shares of Common Stock outstanding immediately after giving effect to such exercise. A holder <span style="white-space:nowrap">of&#160;Pre-Funded&#160;Warrants</span> may increase or decrease this percentage to a percentage not in excess of 19.99% by providing at least 61 days&#8217; prior notice to the Company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Underwriting Agreement contains customary representations, warranties, covenants and agreements by the Company, customary conditions to closing, indemnification obligations of the Company and the Underwriter, including for liabilities under the Securities Act of 1933, as amended (the &#8220;<span style="font-weight:bold"><span style="font-style:italic">Securities Act</span></span>&#8221;), other obligations of the parties and termination provisions. The representations, warranties and covenants contained in the Underwriting Agreement were made only for purposes of such agreement and as of specific dates, were solely for the benefit of the parties to such agreement, and may be subject to limitations agreed upon by the contracting parties. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A copy of the Underwriting Agreement and the form <span style="white-space:nowrap">of&#160;Pre-Funded&#160;Warrant</span> are filed as Exhibits 1.1 and 4.1, respectively, and are incorporated herein by reference. The foregoing descriptions of the Underwriting Agreement and <span style="white-space:nowrap">the&#160;Pre-Funded&#160;Warrants</span> does not purport to be complete and are qualified in their entirety by reference to such exhibits. A copy of the opinion of Cooley LLP relating to the legality of the securities issued and sold in the Offering is filed herewith as Exhibit 5.1. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On December 20, 2023, the Company issued a press release announcing the Offering, a copy of which is filed as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">10-K</span> and is incorporated herein by reference. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Caution Concerning Forward Looking Statements </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Current Report on <span style="white-space:nowrap">Form&#160;8-K&#160;may</span> contain forward-looking statements made in reliance upon the safe harbor provisions of Section&#160;27A of the Securities Act and Section&#160;21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can be identified by the use of words such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;anticipate,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;potential,&#8221; &#8220;should,&#8221; &#8220;continue&#8221; or the negative versions of those words or other comparable words. These forward-looking statements include statements about the Offering, such as the expected gross proceeds and anticipated closing date. These forward-looking statements are based on information currently available to the Company and its current plans or expectations, and are subject to a number of uncertainties and risks that could significantly affect current plans. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all. The Company&#8217;s forward-looking statements also involve assumptions that, if they prove incorrect, would cause its results to differ materially from those expressed or implied by such forward-looking statements. These and other risks concerning the Company&#8217;s business </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">are described in additional detail in the Company&#8217;s Annual Report on <span style="white-space:nowrap">Form&#160;10-K&#160;for</span> the year ended December&#160;31, 2022, the Company&#8217;s Quarterly Report on Form <span style="white-space:nowrap">10-Q</span> for the quarter ended September&#160;30, 2023 and in the Company&#8217;s other Periodic and Current Reports filed with the Securities and Exchange Commission. The Company is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise. </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#160;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td style="width:92%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Number</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"><span style="font-weight:bold">Exhibit&#160;Description</span></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;1.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d456025dex11.htm">Underwriting Agreement, dated December 20, 2023, by and between the Company, Jefferies LLC and Cowen and Company, LLC. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d456025dex41.htm">Form of <span style="white-space:nowrap">Pre-Funded</span> Warrant. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#160;&#160;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d456025dex51.htm">Opinion of Cooley LLP. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d456025dex51.htm">Consent of Cooley LLP (included in Exhibit&#160;5.1). </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d456025dex991.htm">Press Release. </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (formatted as inline XBRL).</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURES </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"><span style="font-weight:bold">Annexon,&#160;Inc.</span></td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: December&#160;21, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Jennifer Lew</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Jennifer Lew</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Executive Vice President and Chief Financial Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>d456025dex11.htm
<DESCRIPTION>EX-1.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-1.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 1.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Annexon, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25,035,000 Shares
of Common Stock, par value $0.001 per share </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to Purchase 18,379,861 Shares of
Common Stock </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Underwriting Agreement </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">December&nbsp;20, 2023 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies LLC </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As Representatives of the </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;several Underwriters listed </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">&nbsp;&nbsp;&nbsp;&nbsp;in Schedule 1 hereto </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">c/o</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Jefferies LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">520 Madison Avenue</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York, NY 10179</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="6%"></TD>

<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">c/o</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Cowen and Company, LLC</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">599 Lexington Avenue</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">New York, NY 10002</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Annexon, Inc., a Delaware corporation (the &#147;Company&#148;), proposes to issue and sell to the several underwriters listed in Schedule 1
hereto (the &#147;Underwriters&#148;), for whom Jefferies LLC (&#147;Jefferies&#148;) and Cowen and Company, LLC (&#147;TD Cowen&#148;) are acting as representatives (the &#147;Representatives&#148;), (i) an aggregate of 25,035,000 shares (the
&#147;Offered Shares&#148;) of common stock, par value $0.001 per share (&#147;Common Stock&#148;) and <FONT STYLE="white-space:nowrap">(ii)&nbsp;pre-funded</FONT> warrants to purchase 18,379,861 shares of Common Stock (the <FONT
STYLE="white-space:nowrap">&#147;Pre-Funded</FONT> Warrants&#148;) of the Company; the Offered Shares and the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to be sold by the Company are collectively referred to as the &#147;Offered
Securities&#148;. As used herein, &#147;Warrant Shares&#148; means the shares of Common Stock issuable upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. The shares of Common Stock of the Company to be outstanding
after giving effect to the sale of the Offered Securities are referred to herein as the &#147;Stock&#148;. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company hereby confirms
its agreement with the several Underwriters concerning the purchase and sale of the Offered Securities, as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1.&nbsp;&nbsp;&nbsp;&nbsp;<U>Registration Statement</U>. The Company has prepared and filed with the Securities and Exchange Commission (the
&#147;Commission&#148;) under the Securities Act of 1933, as amended, and the rules and regulations of the Commission thereunder (collectively, the &#147;Securities Act&#148;), a registration statement on Form
<FONT STYLE="white-space:nowrap">S-3,</FONT> as amended (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-258863),</FONT> including a base prospectus (the &#147;Base Prospectus&#148;), relating to certain securities, including the Common Stock, to
be issued from time to time by the Company, and which incorporates by reference certain documents that the Company has filed or will file in accordance with the provisions of the Securities Exchange Act of 1934, as amended, and the rules and
regulations of the Commission thereunder (collectively, the &#147;Exchange Act&#148;). Such registration statement and any post-effective amendment thereto, as amended at the time it became effective, including the information, if any, deemed
pursuant to Rule 430A, 430B or 430C under the Securities Act to be part of </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the registration statement at the time of its effectiveness (&#147;Rule 430 Information&#148;), is referred to herein as the &#147;Registration Statement&#148;; and each preliminary prospectus
supplement used in connection with the offering of the Offered Securities, if any, including the Base Prospectus, are collectively referred to herein as a &#147;preliminary prospectus,&#148; and the term &#147;Prospectus&#148; means the prospectus
supplement in the form first used (or made available upon request of purchasers pursuant to Rule 173 under the Securities Act) in connection with confirmation of sales of the Offered Securities together with the prospectus included in the
Registration Statement at the time of its effectiveness that omitted Rule 430 Information. If the Company has filed an abbreviated registration statement pursuant to Rule 462(b) under the Securities Act (the &#147;Rule 462 Registration
Statement&#148;), then any reference herein to the term &#147;Registration Statement&#148; shall be deemed to include such Rule 462 Registration Statement. Any reference in this underwriting agreement (this &#147;Agreement&#148;) to the Registration
Statement, any preliminary prospectus or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act, as of
the effective date of the Registration Statement or the date of such preliminary prospectus or the Prospectus, as the case may be, and any reference to &#147;amend&#148;, &#147;amendment&#148; or &#147;supplement&#148; with respect to the
Registration Statement, any preliminary prospectus or the Prospectus shall be deemed to refer to and include any documents filed after such date under the Exchange Act that are deemed to be incorporated by reference therein. Capitalized terms used
but not defined herein shall have the meanings given to such terms in the Registration Statement and the Prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At or prior to the
Applicable Time (as defined below), the Company had prepared the following information (collectively with the pricing information set forth on Annex A, the &#147;Pricing Disclosure Package&#148;): the Base Prospectus, as amended or supplemented
immediately prior to the Applicable Time, and each &#147;free-writing prospectus&#148; (as defined pursuant to Rule 405 under the Securities Act) listed on Annex A hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Applicable Time&#148; means 4:30 P.M. [A.M.], New York City time, on December&nbsp;20, 2023. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2.&nbsp;&nbsp;&nbsp;&nbsp;<U>Purchase of the Offered Securities by the Underwriters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;The Company agrees to issue and sell the Offered Securities to the several Underwriters as provided in this
Agreement, and each Underwriter, on the basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees, severally and not jointly, to purchase <U>from the Company (i)</U>&nbsp;at a
purchase price for one Offered Share of $2.7072 and (ii)&nbsp;at a purchase price for one <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant of $2.7063, the respective number of Offered Securities set forth opposite such Underwriter&#146;s
name in Schedule 1 hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;The Company understands that the Underwriters intend to make a public offering of
the Offered Securities, and initially to offer the Offered Securities on the terms set forth in the Pricing Disclosure Package. The Company acknowledges and agrees that the Underwriters may offer and sell Offered Securities to or through any
affiliate of an Underwriter. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;Payment for the Offered Securities shall be made by wire transfer in immediately
available funds to the account specified by the Company to the Representatives in the case of the Offered Securities, at the offices of Latham&nbsp;&amp; Watkins LLP, counsel for the Underwriters (or at such other place as may be agreed to by the
Company and the Representatives) at 10:00 A.M., New York City time, on December&nbsp;26, 2023, or at such other time on the same or such other date, not later than the fifth business day thereafter, as the Representatives and the Company may agree
upon in writing. The time and date of such payment for the Offered Securities is referred to herein as the &#147;Closing Date&#148;. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Payment for the Offered Securities to be purchased on the Closing
Date shall be made against delivery to the Representatives for the respective accounts of the several Underwriters of the Offered Securities to be purchased on such date with any transfer taxes payable in connection with the sale of such Offered
Securities duly paid by the Company. Delivery of the Offered Securities shall be made through the facilities of The Depository Trust Company unless the Representatives shall otherwise instruct. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;The Company acknowledges and agrees that the Representatives and the other Underwriters are acting solely in the
capacity of an arm&#146;s length contractual counterparty to the Company with respect to the offering of Offered Securities contemplated hereby (including in connection with determining the terms of the offering) and not as a financial advisor or a
fiduciary to, or an agent of, the Company or any other person. Additionally, neither the Representatives nor any other Underwriter is advising the Company or any other person as to any legal, tax, investment, accounting or regulatory matters in any
jurisdiction. The Company shall consult with its own advisors concerning such matters and shall be responsible for making its own independent investigation and appraisal of the transactions contemplated hereby, and neither the Representatives nor
the other Underwriters shall have any responsibility or liability to the Company with respect thereto. Any review by the Representatives and the other Underwriters of the Company, the transactions contemplated hereby or other matters relating to
such transactions will be performed solely for the benefit of the Underwriters and shall not be on behalf of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations and Warranties of the Company</U>. The Company represents and warrants to each Underwriter that:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Preliminary Prospectus.</I> No order preventing or suspending the use of any preliminary
prospectus has been issued by the Commission, and any preliminary prospectus included in the Pricing Disclosure Package, at the time of filing thereof, complied in all material respects with the Securities Act, and no preliminary prospectus, at the
time of filing thereof, contained any untrue statement of a material fact or omitted to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;
<U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such
Underwriter through the Representatives expressly for use in any preliminary prospectus, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in Section&nbsp;7(b)
hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Pricing Disclosure Package</I>. The Pricing Disclosure Package as of the Applicable
Time did not, and as of the Closing Date will not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not
misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance upon and in conformity with information relating to any Underwriter furnished to the Company in writing by
such Underwriter through the Representatives expressly for use in such Pricing Disclosure Package, it being understood and agreed that the only such information furnished by any Underwriter consists of the information described as such in
Section&nbsp;7(b) hereof. No statement of material fact included in the Prospectus has been omitted from the Pricing Disclosure Package and no statement of material fact included in the Pricing Disclosure Package that is required to be included in
the Prospectus has been omitted therefrom. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>Issuer Free Writing Prospectus. </I>Other than
the Registration Statement, any preliminary prospectus and the Prospectus, the Company (including its agents and representatives, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
other than the Underwriters in their capacity as such) has not prepared, made, used, authorized, approved or referred to and will not prepare, make, use, authorize, approve or refer to any
&#147;written communication&#148; (as defined in Rule 405 under the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Offered Securities (each such communication by the Company or its agents and representatives
(other than a communication referred to in clause (i)&nbsp;below) an &#147;Issuer Free Writing Prospectus&#148;) other than (i)&nbsp;any document not constituting a prospectus pursuant to Section&nbsp;2(a)(10)(a) of the Securities Act or Rule 134
under the Securities Act or (ii)&nbsp;the documents listed on Annex A hereto, each electronic road show and any other written communications approved in writing in advance by the Representatives. Each such Issuer Free Writing Prospectus complies in
all material respects with the Securities Act, has been or will be (within the time period specified in Rule 433) filed in accordance with the Securities Act (to the extent required thereby) and does not conflict with the information contained in
the Registration Statement or the Pricing Disclosure Package, and, when taken together with any preliminary prospectus accompanying, or delivered prior to delivery of, such Issuer Free Writing Prospectus, did not, and as of the Closing Date will
not, contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company
makes no representation or warranty with respect to any statements or omissions made in each such Issuer Free Writing Prospectus or preliminary prospectus in reliance upon and in conformity with information relating to any Underwriter furnished to
the Company in writing by such Underwriter through the Representatives expressly for use in such Issuer Free Writing Prospectus or preliminary prospectus, it being understood and agreed that the only such information furnished by any Underwriter
consists of the information described as such in Section&nbsp;7(b) hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;[Reserved]. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;
<I><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Materials. </I>The Company (i)&nbsp;has not engaged in any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications and (ii)&nbsp;has not authorized anyone to engage in
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. The Company has not distributed or approved for distribution any Written <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communications. &#147;Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication&#148; means any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication that is a written communication within the meaning of Rule 405 under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<I>Registration Statement and Prospectus.</I> The Company meets the requirements for use of Form <FONT
STYLE="white-space:nowrap">S-3</FONT> under the Securities Act. The Registration Statement has been declared effective by the Commission. No order suspending the effectiveness of the Registration Statement has been issued by the Commission, and no
proceeding for that purpose or pursuant to Section&nbsp;8A of the Securities Act against the Company or related to the offering of the Offered Securities has been initiated or, to the knowledge of the Company, threatened by the Commission; as of the
applicable effective date of the Registration Statement and any post-effective amendment thereto, the Registration Statement and any such post-effective amendment complied and will comply in all material respects with the Securities Act, and did not
and will not contain any untrue statement of a material fact or omit to state a material fact required to be stated therein or necessary in order to make the statements therein not misleading; and as of the date of the Prospectus and any amendment
or supplement thereto and as of the Closing Date the Prospectus complied and will comply in all material respects with the Securities Act and will not contain any untrue statement of a material fact or omit to state a material fact necessary in
order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U> that the Company makes no representation or warranty with respect to any statements or omissions made in reliance
upon and in conformity with information relating to any Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Registration Statement and the Prospectus and any amendment or supplement thereto, it being understood and agreed that the only such information furnished by any Underwriter consists of the
information described as such in Section&nbsp;7(b) hereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<I>Incorporated Documents.</I> The
documents incorporated by reference in the Registration Statement, the Prospectus and the Pricing Disclosure Package, when they were filed with the Commission conformed in all material respects to the requirements of the Exchange Act, and none of
such documents contained any untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading; and any further documents so
filed and incorporated by reference in the Registration Statement, the Prospectus or the Pricing Disclosure Package, when such documents are filed with the Commission, will conform in all material respects to the requirements of the Exchange Act and
will not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made, not misleading. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<I>Financial Statements.</I> The financial statements (including the related notes thereto) of the
Company and its consolidated subsidiaries included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus comply in all material respects with the applicable requirements of the Securities Act
and the Exchange Act, as applicable, and present fairly in all material respects the financial position of the Company and its consolidated subsidiaries as of the dates indicated and the results of their operations and the changes in their cash
flows for the periods specified; such financial statements have been prepared in conformity with generally accepted accounting principles in the United States (&#147;GAAP&#148;) applied on a consistent basis throughout the periods covered thereby,
except in the case of unaudited financial statements, which are subject to normal <FONT STYLE="white-space:nowrap">year-end</FONT> adjustments and do not contain certain footnotes as permitted by the applicable rules of the Commission; and any
supporting schedules included or incorporated by reference in the Registration Statement present fairly in all material respects the information required to be stated therein; and the other financial information included or incorporated by reference
in the Registration Statement, the Pricing Disclosure Package and the Prospectus has been derived from the accounting records of the Company and its consolidated subsidiaries and presents fairly in all material respects the information shown
thereby. No other financial statements or supporting schedules are required to be included in the Registration Statement, the Pricing Disclosure Package and the Prospectus. To the Company&#146;s knowledge, no person who has been suspended or barred
from being associated with a registered public accounting firm, or who has failed to comply with any sanction pursuant to Rule 5300 promulgated by the PCAOB, has participated in or otherwise aided the preparation of, or audited, the financial
statements, supporting schedules or other financial data filed with the Commission as a part of the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Material Adverse Change.</I> Since the date of the most recent financial statements of the
Company included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (i)&nbsp;there has not been any material change in the capital stock (other than the issuance of shares of Common Stock
upon exercise of stock options and warrants and vesting of other equity awards described as outstanding in, and the grant of options and awards under existing equity incentive plans described in, the Registration Statement, the Pricing Disclosure
Package and the Prospectus), short-term debt or long-term debt of the Company or any of its subsidiaries, or any dividend or distribution of any kind declared, set aside for payment, paid or made by the Company on any class of capital stock, or any
material adverse change, or any development that would reasonably be expected to result in a material </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
adverse change, in or affecting the business, properties, management, financial position, stockholders&#146; equity, results of operations or prospects of the Company and its subsidiaries taken
as a whole; (ii)&nbsp;neither the Company nor any of its subsidiaries has entered into any transaction or agreement (whether or not in the ordinary course of business) that is material to the Company and its subsidiaries taken as a whole or incurred
any liability or obligation, direct or contingent, that is material to the Company and its subsidiaries taken as a whole; and (iii)&nbsp;neither the Company nor any of its subsidiaries has sustained any loss or interference with its business that is
material to the Company and its subsidiaries taken as a whole and that is either from fire, explosion, flood or other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any action, order or decree of any court
or arbitrator or governmental or regulatory authority, except in each case as otherwise disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<I>Organization and Good Standing.</I> The Company and each of its subsidiaries have been duly
organized and are validly existing and in good standing under the laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction in which their respective ownership or lease of
property or the conduct of their respective businesses requires such qualification, and have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they are engaged, except where the
failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the business, properties, management, financial position,
stockholders&#146; equity, results of operations or prospects of the Company and its subsidiaries taken as a whole or on the performance by the Company of its obligations under this Agreement (a &#147;Material Adverse Effect&#148;). The Company does
not own or control, directly or indirectly, any corporation, association or other entity other than the subsidiaries listed in Exhibit 21.1 to the Company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended
December&nbsp;31, 2022. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;<I>Capitalization.</I> The Company has an authorized capitalization as
set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus; all the outstanding shares of capital stock of the Company have been duly and validly authorized and issued and are fully paid and <FONT
STYLE="white-space:nowrap">non-assessable</FONT> and are not subject to any <FONT STYLE="white-space:nowrap">pre-emptive</FONT> or similar rights that have not been duly waived or satisfied; except as described in or expressly contemplated by the
Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no outstanding rights (including, without limitation, <FONT STYLE="white-space:nowrap">pre-emptive</FONT> rights), warrants or options to acquire, or instruments
convertible into or exchangeable for, any shares of capital stock or other equity interest in the Company or any of its subsidiaries, or any contract, commitment, agreement, understanding or arrangement of any kind relating to the issuance of any
capital stock of the Company or any such subsidiary, any such convertible or exchangeable securities or any such rights, warrants or options; the capital stock of the Company conforms in all material respects to the description thereof contained in
the Registration Statement, the Pricing Disclosure Package and the Prospectus; and all the outstanding shares of capital stock or other equity interests of each subsidiary owned, directly or indirectly, by the Company have been duly and validly
authorized and issued, are fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> (except, in the case of any foreign subsidiary, for directors&#146; qualifying shares) and are owned directly or indirectly by the Company, free and
clear of any lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim of any third party. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;<I>Stock Options. </I>With respect to the stock options (the &#147;Stock Options&#148;) granted
pursuant to the stock-based compensation plans of the Company and its subsidiaries (the &#147;Company Stock Plans&#148;), except as would not, individually or in the aggregate, reasonably be </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
expected to have a Material Adverse Effect, (i)&nbsp;each Stock Option intended to qualify as an &#147;incentive stock option&#148; under Section&nbsp;422 of the Internal Revenue Code of 1986, as
amended (the &#147;Code&#148;) so qualifies, (ii)&nbsp;each grant of a Stock Option was duly authorized no later than the date on which the grant of such Stock Option was by its terms to be effective by all necessary corporate action, including, as
applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee thereof) and any required stockholder approval by the necessary number of votes or written consents, and the award agreement governing such
grant (if any) was duly executed and delivered by each party thereto, (iii)&nbsp;each such grant was made in accordance with the terms of the Company Stock Plans, the Exchange Act and all other applicable laws and regulatory rules or requirements,
and (iv)&nbsp;each such grant was properly accounted for in accordance with GAAP in the financial statements (including the related notes) of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;<I>Due Authorization.</I> The Company has full right, power and authority to execute and deliver
this Agreement and the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and to perform its obligations hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by it of this Agreement and
the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and the consummation by it of the transactions contemplated hereby has been duly and validly taken. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp;<I>The Transaction Documents. </I>This Agreement and the
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants have been duly authorized, executed and delivered by the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(o)&nbsp;&nbsp;&nbsp;&nbsp;<I>The Offered Securities. </I>The Offered Shares to be issued and sold by the Company hereunder
have been duly authorized by the Company and, when issued and delivered and paid for as provided herein, will be duly and validly issued, will be fully paid and <FONT STYLE="white-space:nowrap">non-assessable</FONT> and will conform in all material
respects to the descriptions thereof in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and the issuance of the Offered Shares is not subject to any preemptive or similar rights that have not been duly waived or
satisfied. The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants to be issued and sold by the Company hereunder have been duly authorized by the Company and, when executed and delivered by the Company, will be valid and binding agreements
of the Company, enforceable against the Company in accordance with their terms. The Warrant Shares have been duly authorized and validly reserved for issuance upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants in a
number sufficient to meet the current exercise requirements. The Warrant Shares, when issued and delivered upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, and in accordance therewith, will be duly and validly
issued, will be fully paid and <FONT STYLE="white-space:nowrap">non-assessable,</FONT> will conform in all material respects to the descriptions thereof in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and the
issuance of the Warrant Shares is not subject to any preemptive or similar rights that have not been duly waived or satisfied. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(p)&nbsp;&nbsp;&nbsp;&nbsp;<I>Listing. </I>The Common Stock and Warrant Shares are listed on The Nasdaq Global Select Market,
and the Company has taken no action designed to, or reasonably likely to have the effect of, delisting the Common Stock from The Nasdaq Global Select Market, nor has the Company received any notification that The Nasdaq Stock Market
(&#147;Nasdaq&#148;) is contemplating terminating such listing. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(q)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Violation or Default.</I>
Neither the Company nor any of its subsidiaries is (i)&nbsp;in violation of its charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents; (ii)&nbsp;in default, and no event has occurred that, with notice or
lapse of time or both, would constitute such a default, in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company
or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which any property or asset of the Company or any of its subsidiaries is subject; or (iii)&nbsp;in violation of any law or
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (ii)&nbsp;and (iii) above, for any such
default or violation that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(r)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Conflicts. </I>The execution, delivery and performance by the Company of this Agreement, the
issuance and sale of the Offered Securities and the consummation of the transactions contemplated by this Agreement or the Pricing Disclosure Package and the Prospectus will not (i)&nbsp;conflict with or result in a breach or violation of any of the
terms or provisions of, or constitute a default under, result in the termination, modification or acceleration of, or result in the creation or imposition of any lien, charge or encumbrance upon any property, right or asset of the Company or any of
its subsidiaries pursuant to, any indenture, mortgage, deed of trust, loan agreement or other agreement or instrument to which the Company or any of its subsidiaries is a party or by which the Company or any of its subsidiaries is bound or to which
any property, right or asset of the Company or any of its subsidiaries is subject, (ii)&nbsp;result in any violation of the provisions of the charter or <FONT STYLE="white-space:nowrap">by-laws</FONT> or similar organizational documents of the
Company or any of its subsidiaries or (iii)&nbsp;result in the violation of any law or statute or any judgment, order, rule or regulation of any court or arbitrator or governmental or regulatory authority, except, in the case of clauses (i)&nbsp;and
(iii) above, for any such conflict, breach, violation, default, lien, charge or encumbrance that would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(s)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Consents Required.</I> No consent, filing, approval, authorization, order, license,
registration or qualification of or with any court or arbitrator or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this Agreement and the
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, the issuance and sale of the Offered Securities and the consummation of the transactions contemplated by this Agreement and the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants,
except for the registration of the Offered Securities under the Securities Act and such consents, approvals, authorizations, orders and registrations or qualifications as may be required by the Financial Industry Regulatory Authority, Inc.
(&#147;FINRA&#148;) and under applicable state securities laws in connection with the purchase and distribution of the Offered Securities by the Underwriters. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(t)&nbsp;&nbsp;&nbsp;&nbsp;<I>Legal Proceedings.</I> There are no legal, governmental or regulatory investigations, actions,
demands, claims, suits, arbitrations, inquiries or proceedings (&#147;Actions&#148;) pending to which the Company or any of its subsidiaries is or may reasonably be expected to become a party or to which any property of the Company or any of its
subsidiaries is or may reasonably be expected to become the subject that, individually or in the aggregate, if determined adversely to the Company or any of its subsidiaries, would reasonably be expected to have a Material Adverse Effect; to the
knowledge of the Company, no such Actions are threatened or contemplated by any governmental or regulatory authority or threatened by others; and (i)&nbsp;there are no current or pending Actions that are required under the Securities Act to be
described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so described in the Registration Statement, the Pricing Disclosure Package and the Prospectus and (ii)&nbsp;there are no statutes, regulations or
contracts or other documents that are required under the Securities Act to be filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that are not so filed as
exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(u)&nbsp;&nbsp;&nbsp;&nbsp;<I>Independent Accountants</I>. KPMG LLP, who has certified certain financial statements of the
Company and its subsidiaries is an independent registered public accounting firm </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
with respect to the Company and its subsidiaries within the applicable rules and regulations adopted by the Commission and the Public Company Accounting Oversight Board (United States) and as
required by the Securities Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(v)&nbsp;&nbsp;&nbsp;&nbsp;<I>Title to Real and Personal Property</I>. The Company and its
subsidiaries have good and marketable title in fee simple (in the case of real property) to, or have valid rights to lease or otherwise use, all items of real and personal property and assets that are material to the respective businesses of the
Company and its subsidiaries, in each case free and clear of all liens, encumbrances, claims and defects and imperfections of title except those that (i)&nbsp;do not materially interfere with the use made and proposed to be made of such property by
the Company and its subsidiaries or (ii)&nbsp;would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(w)&nbsp;&nbsp;&nbsp;&nbsp;<I>Intellectual Property</I>. Except as disclosed in the Registration Statement, the Pricing
Disclosure Package and the Prospectus, the Company and its subsidiaries own, or possess valid and enforceable licensed rights to use, all material patents, patent applications, trademarks, service marks, trade names, trademark registrations, service
mark registrations, trade dress, designs, data, database rights, Internet domain names, copyrights, works of authorship, licenses, proprietary information and <FONT STYLE="white-space:nowrap">know-how</FONT> (including trade secrets and other
unpatented and/or unpatentable proprietary or confidential information, systems or procedures) necessary for the conduct of their respective businesses as currently conducted and as proposed in the Registration Statement, the Pricing Disclosure
Package and the Prospectus to be conducted (collectively, &#147;Intellectual Property&#148;). The Intellectual Property of the Company has not been adjudged by a court of competent jurisdiction to be invalid or unenforceable, in whole or in part,
and the Company is unaware of any facts which would form a reasonable basis for any such adjudication. The Company and its subsidiaries have not received any notice of any claim of infringement, misappropriation or conflict with any intellectual
property rights of another, and the Company is unaware of any facts which would form a reasonable basis for any such notice or claim. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, to the
Company&#146;s knowledge: (i)&nbsp;there are no third parties who have rights to any Intellectual Property, except for customary reversionary rights of third-party licensors with respect to Intellectual Property that is disclosed in the Registration
Statement, the Pricing Disclosure Package and the Prospectus as owned by or licensed to the Company or its subsidiaries; and (ii)&nbsp;there is no infringement by third parties of any Intellectual Property. Except as disclosed in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, there is no pending or, to the Company&#146;s knowledge, threatened action, suit, proceeding or claim by others: (A)&nbsp;challenging the Company&#146;s rights in or to any Intellectual
Property, and the Company is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; (B)&nbsp;challenging the validity, enforceability or scope of any Intellectual Property, and the Company is unaware
of any facts which would form a reasonable basis for any such action, suit, proceeding or claim; or (C)&nbsp;asserting that the Company or its subsidiaries infringe, misappropriate, or otherwise violate, or would, upon the commercialization of any
product candidate or service described in the Registration Statement, the Pricing Disclosure Package and the Prospectus as under development, infringe, misappropriate, or otherwise violate, any intellectual property rights of others, and the Company
is unaware of any facts which would form a reasonable basis for any such action, suit, proceeding or claim. The Company and its subsidiaries have complied with the terms of each agreement in all material respects pursuant to which Intellectual
Property has been licensed to the Company or its subsidiaries, and all such agreements are in full force and effect. To the Company&#146;s knowledge, there are no material defects in any of the patents or patent applications included in the
Intellectual Property. The patents and patent applications included in the Intellectual Property are subsisting and have not lapsed and the patent applications in the Intellectual Property are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
subsisting and have not been abandoned. The Company and its subsidiaries have taken all reasonable steps to protect, maintain and safeguard their Intellectual Property, including having a policy
to execute appropriate nondisclosure, confidentiality agreements and invention assignment agreements and invention assignments with their employees, and, to the Company&#146;s knowledge, no employee of the Company is in or has been in violation of
any term of any employment contract, patent disclosure agreement, invention assignment agreement, <FONT STYLE="white-space:nowrap">non-competition</FONT> agreement, <FONT STYLE="white-space:nowrap">non-solicitation</FONT> agreement, nondisclosure
agreement, or any restrictive covenant to or with a former employer where the basis of such violation relates to such employee&#146;s employment with the Company. To the Company&#146;s knowledge, the duty of candor and good faith as required by the
United States Patent and Trademark Office during the prosecution of the Company owned United States patents and patent applications included in the Intellectual Property have been complied with; and in all foreign offices having similar
requirements, all such requirements have been complied with for the Company owned foreign patents and patent applications included in the Intellectual Property. To the Company&#146;s knowledge, none of the Company-owned Intellectual Property
employed by the Company or its subsidiaries has been obtained or is being used by the Company or its subsidiary in violation of any material contractual obligation binding on the Company or its subsidiaries or any of their respective officers,
directors or employees. The product candidates described in the Registration Statement, the Pricing Disclosure Package and the Prospectus as under development by the Company or its subsidiaries fall within the scope of the claims of one or more
patents or patent applications owned by, or exclusively licensed to, the Company or its subsidiaries. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(x)&nbsp;&nbsp;&nbsp;&nbsp;<I>Trade Secrets</I>. The Company and its subsidiaries have taken reasonable and customary actions
to protect their rights in and prevent the unauthorized use and disclosure of material trade secrets and confidential business information (including confidential source code, ideas, research and development information, <FONT
STYLE="white-space:nowrap">know-how,</FONT> formulas, compositions, technical data, designs, drawings, specifications, research records, records of inventions, test information, financial, marketing and business data, customer and supplier lists and
information, pricing and cost information, business and marketing plans and proposals) owned by the Company and its subsidiaries, and, to the knowledge of the Company, there has been no unauthorized use or disclosure. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(y)&nbsp;&nbsp;&nbsp;&nbsp;<I> IT Assets</I>. Except as would not reasonably be expected to have a Material Adverse Effect,
(i)&nbsp;the computers, software, hardware, applications, databases, servers, networks, data communications lines, and other information technology assets or systems owned, licensed, leased or otherwise used by the Company or its subsidiaries
(excluding any public networks) (collectively, the &#147;IT Assets&#148;) are adequate for, and operate and perform as is necessary for the operation of the business of the Company and its subsidiaries as currently conducted and as proposed to be
conducted as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus and (ii)&nbsp;to the knowledge of the Company, such IT Assets are not infected by viruses, disabling code or other harmful code. The Company and
its subsidiaries have implemented and maintained commercially reasonable controls, policies, procedures, and safeguards (a)&nbsp;designed to maintain and protect Personal Data (as defined below) and sensitive, confidential or regulated information
(collectively, &#147;Confidential Data&#148;) and the integrity, continuous operation, redundancy and security of all IT Assets used in connection with their businesses and (b)&nbsp;for taking commercially reasonable steps to confirm, audit, verify,
or otherwise ensure the security of any third party service providers. To the knowledge of the Company, there have been no actual or alleged breaches, violations, outages or unauthorized uses of or accesses to same, except for those that have been
remedied without material cost or liability or the duty to notify any other person, nor any incidents under internal review or investigations relating to the same. Neither the Company nor its subsidiaries have been notified of, and each of them have
no </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
knowledge of, any event or condition that could result in, any security incident or breach, violation, outage or unauthorized use or access to the IT Assets and Confidential Data, except as would
not reasonably be expected to have a Material Adverse Effect. &#147;Personal Data&#148; means any information that constitutes &#147;personal data&#148;, &#147;personal information&#148;, &#147;personally identifiable information&#148;,
&#147;protected health information&#148; under applicable law. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(z)&nbsp;&nbsp;&nbsp;&nbsp;<I>Data Privacy and Security
Laws</I>. Except where <FONT STYLE="white-space:nowrap">non-compliance</FONT> would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, the Company and its subsidiaries are, and have since
February&nbsp;1, 2020 been, in compliance with all applicable state, federal, and foreign data privacy, security and consumer protection laws and regulations, including without limitation, to the extent applicable, the Health Insurance Portability
and Accountability Act of 1996 (&#147;HIPAA&#148;) as amended by the Health Information Technology for Economic and Clinical Health Act (the &#147;HITECH Act&#148;), the California Consumer Privacy Act of 2018 (&#147;CCPA&#148;) and California
Privacy Rights Act of 2020 (&#147;CPRA&#148;), the Virginia Consumer Data Protection Act (the &#147;VCDPA&#148;), the Colorado Privacy Rights Act (the &#147;CPA&#148;), the Connecticut Data Privacy Act (&#147;CDPA&#148;), the Utah Consumer Privacy
Act (the &#147;UCPA&#148;), and the European Union General Data Protection Regulation (&#147;GDPR&#148;) (EU 2016/679) (collectively, the &#147;Privacy Laws&#148;) and all policies, and contractual obligations relating to the privacy and security of
IT Assets and Confidential Data, including the collection, storage, transfer (including, without limitation, any transfer across national borders), processing and/or use of Confidential Data and, and to the protection of such IT Assets and
Confidential Data from unauthorized use, access, misappropriation or modification (collectively, with the Privacy Laws, the &#147;Data Protection Requirements&#148;). Except as would not, individually or in the aggregate, reasonably be expected to
have a Material Adverse Effect, the Company and its subsidiaries have since February&nbsp;1, 2020 made all disclosures to users or customers required by Privacy Laws, and none of such disclosures have, to the knowledge of the Company, been
inaccurate or in violation of Privacy Laws. Neither the Company nor any subsidiary: (i)&nbsp;has received written notice of any actual or potential liability, including, but not limited to security or data privacy breaches or other unauthorized or
unlawful access to, use of, or destruction of its Confidential Data or Personal Data, under or relating to, or actual or potential violation of, any Data Protection Requirement, and to the Company&#146;s knowledge, no such notices are threatened or
pending; (ii)&nbsp;is currently conducting or paying for, in whole or in part, any investigation, remediation, or other corrective action pursuant to any Data Protection Requirement; or (iii)&nbsp;is a party to any order, decree, or agreement with
any governmental, regulatory or supervisory authority or body that imposes any obligation or liability under any Data Protection Requirement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aa)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Complaints</I>. There is no complaint to or audit, proceeding, investigation (formal or
informal) or claim currently pending against the Company or its subsidiaries, or to the knowledge of the Company, any of its customers (specific to the customer&#146;s use of the products or services of the Company) by any state Attorney General or
related office, the Federal Trade Commission, the U.S. Department of Health and Human Services and any office contained therein (&#147;HHS&#148;), or any similar authority in any jurisdiction other than the United States or any other governmental
entity, or by any person in respect of the collection, use or disclosure of Personal Data by the Company or its subsidiaries, and, to the knowledge of the Company, no such complaint, audit, proceeding, investigation or claim is threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bb)&nbsp;&nbsp;&nbsp;&nbsp;<I>FDA Compliance</I>. Except in each case, as would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect, the Company: (A)&nbsp;is, and has since February&nbsp;1, 2020 been, in compliance with all applicable statutes, rules or regulations of the FDA relating to the ownership, testing,
development, manufacture, packaging, processing, use, distribution, marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
of any product under development, manufactured or distributed by the Company (&#147;Applicable Laws&#148;); (B) has not received any FDA Form 483, written notice of adverse finding, warning
letter, untitled letter or other correspondence or written notice from the FDA or any similar governmental entity in each case alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals,
clearances, exemptions, authorizations, permits and supplements or amendments thereto required by any such Applicable Laws (&#147;Authorizations&#148;); (C) possesses all Authorizations required for the conduct of its business and such
Authorizations are valid and in full force and effect and the Company is not in violation of any term of any such Authorizations; (D)&nbsp;has not received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation,
arbitration or other action from the FDA or any governmental entity or third party alleging that any product operation or activity is in material violation of any Applicable Laws or Authorizations and has no knowledge that the FDA or any
governmental entity or third party has threatened any such claim, litigation, arbitration, action, suit, investigation or proceeding; and (E)&nbsp;has not received written notice that the FDA or any governmental entity has taken, is taking or
intends to take action to limit, suspend, modify or revoke any material Authorizations and has no knowledge that the FDA or any governmental entity is considering such action. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(cc)&nbsp;&nbsp;&nbsp;&nbsp;<I>Tests and Preclinical and Clinical Trials</I>. The studies, tests and preclinical and clinical
trials conducted by or, to the Company&#146;s knowledge, on behalf of the Company were and, if still ongoing, are being conducted in all material respects in accordance with experimental protocols, procedures and controls pursuant to, where
applicable, all Applicable Laws, including, without limitation, the Federal Food, Drug and Cosmetic Act and the rules and regulations promulgated thereunder and any applicable rules and regulations of the jurisdiction in which such trials and
studies are being conducted; except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, the Company is not aware of any studies, tests or trials, the results of which the Company believes
materially call into question the study, test, or trial results described or referred to in the Registration Statement, the Pricing Disclosure Package and the Prospectus when viewed in the context in which such results are described and the clinical
state of development; and, except to the extent disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus, the Company has not received any written notices or correspondence from the FDA or any governmental entity
requiring the termination or suspension of any studies, tests or preclinical or clinical trials conducted by or on behalf of the Company, other than ordinary course communications with respect to modifications in connection with the design and
implementation of such trials. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(dd)&nbsp;&nbsp;&nbsp;&nbsp;<I>Compliance with Health Care Laws</I>. Except as disclosed in
the Registration Statement, the Pricing Disclosure Package and the Prospectus, and except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect: the Company and its subsidiaries are, and have since
February&nbsp;1, 2020 been, in compliance with all Health Care Laws. For purposes of this Agreement, &#147;Health Care Laws&#148; means: (i)&nbsp;the Federal Food, Drug, and Cosmetic Act and the regulations promulgated thereunder; (ii)&nbsp;the
Public Health Service Act (42 U.S.C. Section&nbsp;201 et seq.), and (iii)&nbsp;all applicable federal, state, local and foreign health care fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback Statute (42 U.S.C. <FONT
STYLE="white-space:nowrap">Section&nbsp;1320a-7b(b)),</FONT> the U.S. Civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), the criminal False Statements Law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7b(a)),</FONT> 18
U.S.C. Sections 286, 287, 1035, 1347, and 1349 the health care fraud criminal provisions under HIPAA , the civil monetary penalties law (42 U.S.C. <FONT STYLE="white-space:nowrap">Section&nbsp;1320a-7a),</FONT> the exclusions law (42 U.S.C. <FONT
STYLE="white-space:nowrap">Section&nbsp;1320a-7),</FONT> and the Physician Payments Sunshine Act (42 U.S.C <FONT STYLE="white-space:nowrap">Section&nbsp;1320-7h);</FONT> and the regulations promulgated pursuant to such laws. Neither the Company nor
any of its subsidiaries has received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from any court or arbitrator or governmental or regulatory authority or third party alleging
that any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
product operation or activity is in material violation of any Health Care Laws nor, to the Company&#146;s knowledge, has any such claim, action, suit, proceeding, hearing, enforcement,
investigation, arbitration or other action been threatened. Except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, the Company and its subsidiaries have filed, maintained or submitted all
reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and
supplements or amendments were complete and accurate on the date filed in all respects (or were corrected or supplemented by a subsequent submission). Neither the Company nor any of its subsidiaries, or any of their respective employees, officers,
directors, or to the Company&#146;s knowledge, any of their respective agents, is a party to any corporate integrity agreements, monitoring agreements, consent decrees, settlement orders, or similar agreements with or imposed by any governmental or
regulatory authority. Additionally, neither the Company nor any of its subsidiaries nor any of their respective employees, officers, directors, or to the Company&#146;s knowledge, its agents, has been excluded, suspended or debarred from
participation in any U.S. federal health care program or human clinical research or, to the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that would reasonably be expected to
result in debarment, suspension, or exclusion. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ee)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Undisclosed Relationships</I>. No
relationship, direct or indirect, exists between or among the Company or any of its subsidiaries, on the one hand, and the directors, officers, stockholders, customers, suppliers or other affiliates of the Company or any of its subsidiaries, on the
other, that is required by the Securities Act to be described in each of the Registration Statement and the Prospectus and that is not so described in such documents and in the Pricing Disclosure Package. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ff)&nbsp;&nbsp;&nbsp;&nbsp;<I>Investment Company Act</I>. The Company is not and, after giving effect to the offering and sale
of the Offered Securities and the application of the proceeds thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be required to register as an &#147;investment company&#148; or an entity
&#147;controlled&#148; by an &#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended, and the rules and regulations of the Commission thereunder. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(gg)&nbsp;&nbsp;&nbsp;&nbsp;<I>Taxes.</I> The Company has filed all tax returns required to be filed by it through the date
hereof, or has duly requested extensions thereof (except where the failure to file would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect), and has paid all taxes shown as due thereon (except for cases
in which the failure to file or pay would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect or, except as currently being contested in good faith through appropriate proceedings and for which reserves
required by U.S. GAAP have been created in the financial statements of the Company), and all such tax returns are true and correct in all material respects. No deficiencies for taxes of the Company have been assessed by a tax authority, and no
deficiencies for taxes of the Company have, to the Company&#146;s knowledge, been proposed by a tax authority, except for such deficiencies as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(hh)&nbsp;&nbsp;&nbsp;&nbsp;<I>Licenses and Permits.</I> The Company and its subsidiaries possess all licenses,
certificates, permits and other authorizations issued by, and have made all declarations and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities that are necessary for the ownership or lease of their
respective properties or the conduct of their respective businesses as described in each of the Registration Statement, the Pricing Disclosure Package and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
the Prospectus, except where the failure to possess or make the same would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; neither the Company nor
any of its subsidiaries has received written notice of any revocation or modification of any such license, certificate, permit or authorization or has any reason to believe that any such license, certificate, permit or authorization will not be
renewed in the ordinary course, except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. To the Company&#146;s knowledge, no party granting any such licenses, certificates, permits or other
authorizations has taken any action to limit, suspend or revoke the same in any material respect. Except as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect, the Company and its subsidiaries have
filed, obtained, maintained or submitted all reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required and all such reports, documents, forms, notices, applications, records, claims,
submissions and supplements or amendments were timely, complete and correct on the date filed (or were corrected or supplemented by a subsequent submission) as required for maintenance of their licenses, certificates, permits and other
authorizations that are necessary for the conduct of their respective businesses. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Labor
Disputes.</I> (i)&nbsp;No labor disturbance by or dispute with employees of the Company or any of its subsidiaries exists or, to the knowledge of the Company, is contemplated or threatened, and (ii)&nbsp;the Company is not aware of any existing or
imminent labor disturbance by, or dispute with, the employees of any of its or its subsidiaries&#146; principal suppliers, contractors or customers, except in the case of each of (i)&nbsp;and (ii) above, as would not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(jj)&nbsp;&nbsp;&nbsp;&nbsp;<I>Certain Environmental
Matters. </I>(i)&nbsp;The Company and its subsidiaries (x)&nbsp;are in compliance with all, and have not violated any, applicable federal, state, local and foreign laws, rules, regulations, requirements, decisions, judgments, decrees, orders and
other legally enforceable requirements relating to pollution or the protection of human health or safety, the environment, natural resources, hazardous or toxic substances or wastes, pollutants or contaminants (collectively, &#147;Environmental
Laws&#148;); (y) have received and are in compliance with all, and have not violated any, permits, licenses, certificates or other authorizations or approvals required of them under any Environmental Laws to conduct their respective businesses; and
(z)&nbsp;have not received written notice of any actual or potential liability or obligation under or relating to, or any actual or potential violation of, any Environmental Laws, including for the investigation or remediation of any disposal or
release of hazardous or toxic substances or wastes, pollutants or contaminants, and have no knowledge of any event or condition that would reasonably be expected to result in any such notice; (ii)&nbsp;there are no costs or liabilities associated
with Environmental Laws of or relating to the Company or its subsidiaries, except in the case of each of (i)&nbsp;and (ii) above, for any such matter as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse
Effect; and (iii)&nbsp;(x) there is no proceeding that is pending, or that is known by the Company to be contemplated, against the Company or any of its subsidiaries under any Environmental Laws in which a governmental entity is also a party, other
than such proceeding regarding which the Company reasonably believes no monetary sanctions of $100,000 or more will be imposed, (y)&nbsp;the Company and its subsidiaries are not aware of any facts or issues regarding compliance with Environmental
Laws, or liabilities or other obligations under Environmental Laws or concerning hazardous or toxic substances or wastes, pollutants or contaminants, that would reasonably be expected to have a Material Adverse Effect, and (z)&nbsp;none of the
Company or its subsidiaries anticipates material capital expenditures relating to any Environmental Laws. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(kk)&nbsp;&nbsp;&nbsp;&nbsp;<I>Hazardous Materials</I>. There has been no
storage, generation, transportation, use, handling, treatment, Release or threat of Release of Hazardous Materials by, relating to or caused by the Company or any of its subsidiaries (or, to the knowledge of the Company and its subsidiaries, any
other entity (including any predecessor) for whose acts or omissions the Company or any of its subsidiaries is or could reasonably be expected to be liable) at, on, under or from any property or facility now or previously owned, operated or leased
by the Company or any of its subsidiaries, or at, on, under or from any other property or facility, in violation of any Environmental Laws or in a manner or amount or to a location that could reasonably be expected to result in any liability under
any Environmental Law, except for any violation or liability which would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. &#147;Hazardous Materials&#148; means any material, chemical, substance, waste,
pollutant, contaminant, compound, mixture, or constituent thereof, in any form or amount, including petroleum (including crude oil or any fraction thereof) and petroleum products, natural gas liquids, asbestos and asbestos containing materials,
naturally occurring radioactive materials, brine, and drilling mud, regulated or which can give rise to liability under any Environmental Law. &#147;Release&#148; means any spilling, leaking, seepage, pumping, pouring, emitting, emptying,
discharging, injecting, escaping, leaching, dumping, disposing, depositing, dispersing, or migrating in, into or through the environment, or in, into from or through any building or structure. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ll)&nbsp;&nbsp;&nbsp;&nbsp;<I>Compliance with ERISA.</I> (i)&nbsp;Each employee benefit plan, within the meaning of
Section&nbsp;3(3) of the Employee Retirement Income Security Act of 1974, as amended (&#147;ERISA&#148;), for which the Company or any member of its &#147;Controlled Group&#148; (defined as any entity, whether or not incorporated, that is under
common control with the Company within the meaning of Section&nbsp;4001(a)(14) of ERISA or any entity that would be regarded as a single employer with the Company under Section&nbsp;414(b),(c),(m) or (o)&nbsp;of the Code) would have any liability
(each, a &#147;Plan&#148;) has been maintained in compliance with its terms and the requirements of any applicable statutes, orders, rules and regulations, including but not limited to ERISA and the Code; (ii)&nbsp;no prohibited transaction, within
the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of the Code, has occurred with respect to any Plan, excluding transactions effected pursuant to a statutory or administrative exemption; (iii)&nbsp;for each Plan that is subject to the
funding rules of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA, no Plan has failed (whether or not waived), or is reasonably expected to fail, to satisfy the minimum funding standards (within the meaning of Section&nbsp;302 of ERISA or
Section&nbsp;412 of the Code) applicable to such Plan; (iv)&nbsp;no Plan is, or is reasonably expected to be, in &#147;at risk status&#148; (within the meaning of Section&nbsp;303(i) of ERISA) and no Plan that is a &#147;multiemployer plan&#148;
within the meaning of Section&nbsp;4001(a)(3) of ERISA is in &#147;endangered status&#148; or &#147;critical status&#148; (within the meaning of Sections 304 and 305 of ERISA)&nbsp;(v) the fair market value of the assets of each Plan exceeds the
present value of all benefits accrued under such Plan (determined based on those assumptions used to fund such Plan); (vi) no &#147;reportable event&#148; (within the meaning of Section&nbsp;4043(c) of ERISA and the regulations promulgated
thereunder) has occurred or is reasonably expected to occur; (vii)&nbsp;each Plan that is intended to be qualified under Section&nbsp;401(a) of the Code has received a favorable determination letter, or is entitled to rely on an opinion letter, from
the Internal Revenue Service, and, to the knowledge of the Company, nothing has occurred, whether by action or by failure to act, which would cause the loss of such qualification; (viii)&nbsp;neither the Company nor any member of the Controlled
Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions to the Plan or premiums to the Pension Benefit Guarantee Corporation, in the ordinary course and without default) in respect of a
Plan (including a &#147;multiemployer plan&#148; within the meaning of Section&nbsp;4001(a)(3) of ERISA); and (ix)&nbsp;none of the following events has occurred or is reasonably likely to occur: (A)&nbsp;a material increase in the aggregate amount
of contributions required to be made to all Plans by the Company or its Controlled Group affiliates in the current fiscal year of the Company and its Controlled Group </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
affiliates compared to the amount of such contributions made in the Company&#146;s and its Controlled Group affiliates&#146; most recently completed fiscal year; or (B)&nbsp;a material increase
in the Company and its subsidiaries&#146; &#147;accumulated post-retirement benefit obligations&#148; (within the meaning of Accounting Standards Codification Topic <FONT STYLE="white-space:nowrap">715-60)</FONT> compared to the amount of such
obligations in the Company and its subsidiaries&#146; most recently completed fiscal year, except in each case with respect to the events or conditions set forth in (i)&nbsp;through (ix) hereof, as would not, individually or in the aggregate,
reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(mm)&nbsp;&nbsp;&nbsp;&nbsp;<I>Disclosure Controls</I>. The
Company and its subsidiaries maintain an effective system of &#147;disclosure controls and procedures&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(e)</FONT> of the Exchange Act) that complies with the requirements of the
Exchange Act and that has been designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified
in the Commission&#146;s rules and forms, including controls and procedures designed to ensure that such information is accumulated and communicated to the Company&#146;s management as appropriate to allow timely decisions regarding required
disclosure. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(nn)&nbsp;&nbsp;&nbsp;&nbsp;<I>Accounting Controls.</I> The Company and its subsidiaries maintain systems of
&#147;internal control over financial reporting&#148; (as defined in Rule <FONT STYLE="white-space:nowrap">13a-15(f)</FONT> of the Exchange Act) that are designed to comply with the requirements of the Exchange Act and have been designed by, or
under the supervision of, their respective principal executive and principal financial officers, or persons performing similar functions, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with GAAP, including, but not limited to, internal accounting controls sufficient to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&#146;s
general or specific authorizations; (ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with GAAP and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in
accordance with management&#146;s general or specific authorization; (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals and appropriate action is taken with respect to any differences; and
(v)&nbsp;interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement, the Prospectus and the Pricing Disclosure Package fairly presents the information called for in all material
respects and is prepared in accordance with the Commission&#146;s rules and guidelines applicable thereto (it being understood that this subsection shall not require the Company to comply with Section&nbsp;404 of the Sarbanes-Oxley Act of 2002, as
amended, as of an earlier date than it would otherwise be required to so comply under applicable law). There are no material weaknesses in the Company&#146;s internal controls. The Company&#146;s auditors and the Audit Committee of the Board of
Directors of the Company have been advised of: (i)&nbsp;all significant deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which have adversely affected or are reasonably likely to adversely
affect the Company&#146;s ability to record, process, summarize and report financial information; and (ii)&nbsp;any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&#146;s
internal controls over financial reporting. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(oo)&nbsp;&nbsp;&nbsp;&nbsp;<I>eXtensible Business Reporting Language. </I>The
interactive data in eXtensible Business Reporting Language included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance with the
Commission&#146;s rules and guidelines applicable thereto. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(pp)&nbsp;&nbsp;&nbsp;&nbsp;<I>Insurance. </I>The Company and
its subsidiaries have insurance covering their respective properties, operations, personnel and businesses, including business interruption </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
insurance, which insurance is in amounts and insures against such losses and risks as are generally maintained by similarly situated companies and which the Company believes are reasonably
adequate to protect the Company and its subsidiaries and their respective businesses; and neither the Company nor any of its subsidiaries has (i)&nbsp;received notice from any insurer or agent of such insurer that capital improvements or other
expenditures are required or necessary to be made in order to continue such insurance or (ii)&nbsp;any reason to believe that it will not be able to renew its existing insurance coverage as and when such coverage expires or to obtain similar
coverage at reasonable cost from similar insurers as may be necessary to continue its business. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(qq)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Unlawful Payments.</I> Neither the Company nor any of its subsidiaries nor any director,
officer, or employee of the Company or any of its subsidiaries nor, to the knowledge of the Company, any agent, affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries has (i)&nbsp;used any corporate
funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity; (ii)&nbsp;made or taken an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or
benefit to any foreign or domestic government or regulatory official or employee, including of any government-owned or controlled entity or of a public international organization, or any person acting in an official capacity for or on behalf of any
of the foregoing, or any political party or party official or candidate for political office; (iii)&nbsp;violated or is in violation of any provision of the U.S. Foreign Corrupt Practices Act of 1977, as amended, or any applicable law or regulation
implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom, or any other applicable anti-bribery or
anti-corruption laws; or (iv)&nbsp;made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or
improper payment or benefit. The Company and its subsidiaries have instituted, maintain and enforce, and will continue to maintain and enforce policies and procedures designed to promote and ensure compliance with all applicable anti-bribery and
anti-corruption laws. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(rr)&nbsp;&nbsp;&nbsp;&nbsp;<I>Compliance with Anti-Money Laundering Laws</I>. The operations of the
Company and its subsidiaries are and have been conducted at all times in compliance with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting Act of 1970, as amended, the
applicable money laundering statutes of all jurisdictions where the Company or any of its subsidiaries conducts business, the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or
enforced by any governmental or regulatory agency (collectively, the &#147;Anti-Money Laundering Laws&#148;) and no action, suit or proceeding by or before any court or governmental or regulatory agency, authority or body or any arbitrator involving
the Company or any of its subsidiaries with respect to the Anti-Money Laundering Laws is pending or, to the knowledge of the Company, threatened. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ss)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Conflicts with Sanctions Laws. </I>Neither the Company nor any of its subsidiaries,
directors, officers or employees, nor, to the knowledge of the Company, any agent, or affiliate or other person associated with or acting on behalf of the Company or any of its subsidiaries is currently the subject or the target of any sanctions
administered or enforced by the U.S. Government, (including, without limitation, the Office of Foreign Assets Control of the U.S. Department of the Treasury or the U.S. Department of State and including, without limitation, the designation as a
&#147;specially designated national&#148; or &#147;blocked person&#148;), the United Nations Security Council, the European Union, His Majesty&#146;s Treasury, or other relevant sanctions authority (collectively, &#147;Sanctions&#148;), nor is the
Company or any of its subsidiaries located, organized or resident in a country or territory that is the subject or the target of Sanctions, including, without </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
limitation, Cuba, Iran, North Korea, Syria, and the Crimea and the <FONT STYLE="white-space:nowrap">so-called</FONT> Donetsk People&#146;s Republic, and
<FONT STYLE="white-space:nowrap">so-called</FONT> Luhansk People&#146;s Republic regions of Ukraine (each, a &#147;Sanctioned Country&#148;); and the Company will not directly or indirectly use the proceeds of the offering of the Offered Securities
hereunder, or lend, contribute or otherwise make available such proceeds to any subsidiary, joint venture partner or other person or entity (i)&nbsp;to fund or facilitate any activities of or business with any person that, at the time of such
funding or facilitation, is the subject or the target of Sanctions, (ii)&nbsp;to fund or facilitate any activities of or business in any Sanctioned Country or (iii)&nbsp;in any other manner that will result in a violation by any person (including
any person participating in the transaction, whether as underwriter, advisor, investor or otherwise) of Sanctions. For the past five years, the Company and its subsidiaries have not knowingly engaged in and are not now knowingly engaged in any
dealings or transactions with any person that at the time of the dealing or transaction is or was the subject or the target of Sanctions or with any Sanctioned Country. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(tt)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Restrictions on Subsidiaries</I>. No subsidiary of the Company is currently prohibited,
directly or indirectly, under any agreement or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution on such subsidiary&#146;s capital stock or similar ownership interest,
from repaying to the Company any loans or advances to such subsidiary from the Company or from transferring any of such subsidiary&#146;s properties or assets to the Company or any other subsidiary of the Company. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(uu)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Broker&#146;s Fees.</I> Neither the Company nor any of its subsidiaries is a party to any
contract, agreement or understanding with any person (other than this Agreement) that would give rise to a valid claim against the Company or any of its subsidiaries or any Underwriter for a brokerage commission, finder&#146;s fee or like payment in
connection with the offering and sale of the Offered Securities. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(vv)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Registration
Rights</I>. No person has the right to require the Company or any of its subsidiaries to register any securities for sale under the Securities Act by reason of the filing of the Registration Statement with the Commission or the issuance and sale of
the Offered Securities, except for such rights as have been waived. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ww)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Stabilization.</I>
Neither the Company nor any of its subsidiaries or, to the Company&#146;s knowledge, affiliates have taken, directly or indirectly, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation
of the price of the shares of Common Stock, whether to facilitate the sale or resale of the Offered Securities or otherwise, and has taken no action which would directly or indirectly violate Regulation M. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(xx)&nbsp;&nbsp;&nbsp;&nbsp;<I>Margin Rules</I>. Neither the issuance, sale and delivery of the Offered Securities nor the
application of the proceeds thereof by the Company as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus will violate Regulation T, U or X of the Board of Governors of the Federal Reserve System or any
other regulation of such Board of Governors. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(yy)&nbsp;&nbsp;&nbsp;&nbsp;<I>Forward-Looking Statements.</I> No
forward-looking statement (within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act) included or incorporated by reference in any of the Registration Statement, the Pricing Disclosure Package or the
Prospectus has been made or reaffirmed without a reasonable basis or has been disclosed other than in good faith and is accompanied by meaningful cautionary statements identifying those factors that could cause actual results to differ materially
from those in such forward-looking statements. No such statement was made with the knowledge of an executive officer or director of the Company that it was false and misleading. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>(zz)</I>&nbsp;&nbsp;&nbsp;&nbsp;<I>Statistical and Market Data.</I>
Nothing has come to the attention of the Company that has caused the Company to believe that the statistical and market-related data included or incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the
Prospectus is not based on or derived from sources that are reliable and accurate in all material respects. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(aaa)&nbsp;&nbsp;&nbsp;&nbsp;<I>Sarbanes-Oxley Act</I>. There is and has been no failure on the part of the Company or any of
the Company&#146;s directors or officers, in their capacities as such, to comply with any applicable provision of the Sarbanes-Oxley Act of 2002, as amended, and the rules and regulations promulgated in connection therewith, including
Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(bbb)&nbsp;&nbsp;&nbsp;&nbsp;<I>Status under the Securities Act</I>. At the time of filing the Registration Statement and any
post-effective amendment thereto, at the earliest time thereafter that the Company or any offering participant made a <I>bona fide</I> offer (within the meaning of Rule 164(h)(2) under the Securities Act) of the Offered Securities and at the date
hereof, the Company was not and is not an &#147;ineligible issuer,&#148; as defined in Rule 405 under the Securities Act. At the time of the initial filing of the Registration Statement, the Company was a well-known seasoned issuer. The Company has
paid the registration fee for this offering pursuant to Rule 457(o) under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ccc)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Ratings</I>. There are (and prior to the Closing Date, will be) no debt securities,
convertible securities or preferred stock issued or guaranteed by the Company or any of its subsidiaries that are rated by a &#147;nationally recognized statistical rating organization&#148;, as such term is defined in Section&nbsp;3(a)(62) of the
Exchange Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ddd)&nbsp;&nbsp;&nbsp;&nbsp;<I>Related-Party Transactions. </I>There are no business relationships or
related-party transactions involving the Company or any of its subsidiaries or any other person required to be described in the Registration Statement, Pricing Disclosure Package or the Prospectus that have not been described as required. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(eee)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Outstanding Loans or Other Extensions of Credit</I>. The Company does not have any
outstanding extension of credit, in the form of a personal loan, to or for any director or executive officer (or equivalent thereof) of the Company except for such extensions of credit as are expressly permitted by Section&nbsp;13(k) of the Exchange
Act. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(fff)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Unlawful Contributions or Other Payments</I><B>.</B> Neither the Company nor any
of its subsidiaries nor, to the best of the Company&#146;s knowledge, any employee or agent of the Company or any subsidiary, has made any contribution or other payment to any official of, or candidate for, any federal, state or foreign office in
violation of any law or of the character required to be disclosed in the Registration Statement, the Pricing Disclosure Package or the Prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ggg)&nbsp;&nbsp;&nbsp;&nbsp;<I>Parties to <FONT STYLE="white-space:nowrap">Lock-Up</FONT> Agreements</I><B>.</B> The Company
has furnished to the Underwriters a letter agreement in the form attached hereto as <U>Exhibit</U><U></U><U>&nbsp;A</U> (the <FONT STYLE="white-space:nowrap">&#147;Lock-up</FONT> Agreement&#148;) from the current officers, directors and certain
securityholders of the Company as agreed with the Representatives. If any additional persons shall become directors or officers of the Company prior to the end of the <FONT STYLE="white-space:nowrap">Lock-up</FONT> Period (as defined in the <FONT
STYLE="white-space:nowrap">Lock-up</FONT> Agreement), the Company shall cause each such person, prior to or contemporaneously with their appointment or election as a director or officer of the Company, to execute and deliver to the Representatives a
<FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.&nbsp;&nbsp;&nbsp;&nbsp;<U>Further Agreements of the Company</U>. The Company covenants
and agrees with each Underwriter that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Required Filings.</I> The Company will file the final
Prospectus with the Commission within the time periods specified by Rule 424(b) and Rule 430A, 430B or 430C under the Securities Act, will file any Issuer Free Writing Prospectus to the extent required by Rule 433 under the Securities Act; the
Company will file promptly all reports and any definitive proxy or information statements required to be filed by the Company with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d) of the Exchange Act subsequent to the date of the
Prospectus and for so long as the delivery of a prospectus is required in connection with the offering or sale of the Offered Securities; and the Company will furnish copies of the Prospectus and each Issuer Free Writing Prospectus (to the extent
not previously delivered) to the Underwriters in New York City prior to 10:00 A.M., New York City time, on the business day next succeeding the date of this Agreement in such quantities as the Representatives may reasonably request. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Delivery of Copies.</I> The Company will deliver, without charge, (i)&nbsp;to the
Representatives, three signed copies of the Registration Statement as originally filed and each amendment thereto, in each case including all exhibits and consents filed therewith and documents incorporated by reference therein; and (ii)&nbsp;to
each Underwriter (A)&nbsp;a conformed copy of the Registration Statement as originally filed and each amendment thereto (without exhibits) and (B)&nbsp;during the Prospectus Delivery Period (as defined below), as many copies of the Prospectus
(including all amendments and supplements thereto and documents incorporated by reference therein and each Issuer Free Writing Prospectus) as the Representatives may reasonably request. As used herein, the term &#147;Prospectus Delivery Period&#148;
means such period of time after the first date of the public offering of the Offered Securities as in the opinion of counsel for the Underwriters a prospectus relating to the Offered Securities is required by law to be delivered (or required to be
delivered but for Rule 172 under the Securities Act) in connection with sales of the Offered Securities by any Underwriter or dealer. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>Amendments or Supplements, Issuer Free Writing Prospectuses.</I> Before preparing, using,
authorizing, approving, referring to or filing any Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement, the Pricing Disclosure Package or the Prospectus, whether before or after the time that
the Registration Statement becomes effective, the Company will furnish to the Representatives and counsel for the Underwriters a copy of the proposed Issuer Free Writing Prospectus, amendment or supplement for review and will not prepare, use,
authorize, approve, refer to or file any such Issuer Free Writing Prospectus or file any such proposed amendment or supplement to which the Representatives reasonably object. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<I>Notice to the Representatives.</I> The Company will advise the Representatives promptly, and
confirm such advice in writing (which may be by electronic mail), (i) when the Registration Statement has become effective; (ii)&nbsp;when any amendment to the Registration Statement has been filed or becomes effective; (iii)&nbsp;when any
supplement to the Pricing Disclosure Package, the Prospectus, any Issuer Free Writing Prospectus, any Written <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or any amendment to the
Prospectus has been filed or distributed; (iv)&nbsp;of any request by the Commission for any amendment to the Registration Statement or any amendment or supplement to the Prospectus or the receipt of any comments from the Commission relating to the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Registration Statement or any other request by the Commission for any additional information including, but not limited to, any request for information concerning any <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication; (v)&nbsp;of the issuance by the Commission or any other governmental or regulatory authority of any order suspending the effectiveness of the
Registration Statement or preventing or suspending the use of any preliminary prospectus, any of the Pricing Disclosure Package, the Prospectus or any Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or the initiation or, to the knowledge of the Company, threatening of any proceeding for that purpose or pursuant to Section&nbsp;8A of
the Securities Act; (vi)&nbsp;of the occurrence of any event or development within the Prospectus Delivery Period as a result of which the Prospectus, the Pricing Disclosure Package or any Issuer Free Writing Prospectus or Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication as then amended or supplemented would include any untrue statement of a material fact or omit to state a material fact necessary in order to
make the statements therein, in the light of the circumstances existing when the Prospectus, the Pricing Disclosure Package, or any such Issuer Free Writing Prospectus or Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication is delivered to a purchaser, not misleading; and (vii)&nbsp;of the receipt by the Company of any notice with respect to any suspension
of the qualification of the Offered Securities for offer and sale in any jurisdiction or the initiation or, to the knowledge of the Company, threatening of any proceeding for such purpose; and the Company will use its best efforts to prevent the
issuance of any such order suspending the effectiveness of the Registration Statement, preventing or suspending the use of any preliminary prospectus, any of the Pricing Disclosure Package or the Prospectus or any Written <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication or suspending any such qualification of the Offered Securities and, if any such order is issued, will obtain as soon as possible the
withdrawal thereof. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<I>Ongoing Compliance.</I> (1)&nbsp;If during the Prospectus Delivery
Period (i)&nbsp;any event or development shall occur or condition shall exist as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact necessary in
order to make the statements therein, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or supplement the Prospectus to comply with law, the Company will
promptly notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission and furnish to the Underwriters and to such dealers as the Representatives may designate such amendments or supplements
to the Prospectus (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the Prospectus as so amended or supplemented (or any document to be filed with the Commission and
incorporated by reference therein) will not, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus will comply with law and (2)&nbsp;if at any time prior to the Closing
Date (i)&nbsp;any event or development shall occur or condition shall exist as a result of which the Pricing Disclosure Package as then amended or supplemented would include any untrue statement of a material fact or omit to state any material fact
necessary in order to make the statements therein, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, not misleading or (ii)&nbsp;it is necessary to amend or supplement the Pricing Disclosure
Package to comply with law, the Company will promptly notify the Underwriters thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission (to the extent required) and furnish to the Underwriters and to such
dealers as the Representatives may designate such amendments or supplements to the Pricing Disclosure Package (or any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the
Pricing Disclosure Package as so amended or supplemented will not, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser, be misleading or so that the Pricing Disclosure Package will comply with
law. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<I>Blue Sky Compliance.</I> The Company will
qualify the Offered Securities for offer and sale under the securities or Blue Sky laws of such jurisdictions as the Representatives shall reasonably request and will continue such qualifications in effect so long as required for distribution of the
Offered Securities; <U>provided</U> that the Company shall not be required to (i)&nbsp;qualify as a foreign corporation or other entity or as a dealer in securities in any such jurisdiction where it would not otherwise be required to so qualify,
(ii)&nbsp;file any general consent to service of process in any such jurisdiction or (iii)&nbsp;subject itself to taxation in any such jurisdiction if it is not otherwise so subject. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<I>Earnings Statement. </I>The Company will make generally available to its securityholders and the
Representatives as soon as practicable an earnings statement that satisfies the provisions of Section&nbsp;11(a) of the Securities Act and Rule 158 of the Commission promulgated thereunder covering a period of at least twelve months beginning with
the first fiscal quarter of the Company occurring after the &#147;effective date&#148; (as defined in Rule 158) of the Registration Statement; <U>provided</U> that the Company will be deemed to have furnished such statements to its securityholders
and the Representatives to the extent they are filed on the Commission&#146;s Electronic Data Gathering, Analysis and Retrieval system (&#147;EDGAR&#148;). </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<I>Clear Market.</I> For a period of 60 days after the date of the Prospectus (the &#147;Restricted
Period&#148;), the Company will not (i)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise transfer or dispose
of, directly or indirectly, or file with, or submit to, the Commission a registration statement under the Securities Act relating to, any shares of Stock or any securities convertible into or exercisable or exchangeable for Stock, or publicly
disclose the intention to make any offer, sale, pledge, disposition, submission or filing, or (ii)&nbsp;enter into any swap, hedging, or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of the Stock
or any such other securities, whether any such transaction described in clause (i)&nbsp;or (ii) above is to be settled by delivery of Stock or such other securities, in cash or otherwise, without the prior written consent of the Representatives;
<U>provided</U>, however, that the foregoing restrictions shall not apply to (1)&nbsp;the Offered Securities to be sold hereunder, (2)&nbsp;the grant or issuance of any shares of Stock or any securities or other awards (including without limitation
options, restricted stock or restricted stock units) convertible into, exercisable for, or that represent the right to receive, shares of Stock pursuant to any Company Stock Plan or otherwise in equity compensation arrangements described in the
Registration Statement and the Prospectus and the issuance of shares of Stock underlying or pursuant to such securities or awards, (3)&nbsp;any shares of Stock issued upon the conversion, exercise (whether such exercise is for cash or
&#147;cashless&#148;), vesting or exchange of convertible, exercisable, exchangeable or other securities outstanding on the date of this Agreement and described in the Registration Statement and the Prospectus granted pursuant to any plan in effect
on the date hereof and described in the Registration Statement and the Prospectus, (4)&nbsp;the filing by the Company of any registration statement on Form <FONT STYLE="white-space:nowrap">S-8</FONT> or a successor form thereto relating to any
Company Stock Plan described in the Registration Statement and the Prospectus, and (5)&nbsp;any shares of Stock or any securities convertible into or exchangeable for, or that represent the right to receive, shares of Stock issued in connection with
any bona fide licensing, commercialization, joint venture, technology transfer, acquisition, development collaboration or partnership or other strategic transaction, <U>provided</U> that the aggregate number of shares of Stock or securities
convertible into or exercisable for Stock (on an <FONT STYLE="white-space:nowrap">as-converted</FONT> or <FONT STYLE="white-space:nowrap">as-exercised</FONT> basis, as the case may be) that the Company may sell or issue or agree to sell or issue as
described in this clause (5)&nbsp;shall not exceed 5% of the total number of shares of Stock issued and outstanding immediately following the completion of the transactions contemplated by this Agreement; <U>provided</U> that the recipient of any
such shares of Stock or securities issued pursuant to clauses (2), (3), and (5)&nbsp;during the Restricted Period shall enter into a <FONT STYLE="white-space:nowrap">&#147;lock-up&#148;</FONT> agreement, substantially in the form of Exhibit A
hereto. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<I>Use of Proceeds.</I> The Company will apply
the net proceeds from the sale of the Offered Securities as described in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus under the heading &#147;Use of Proceeds&#148;. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Stabilization.</I> Neither the Company nor its subsidiaries or affiliates will take, directly
or indirectly, any action designed to or that could reasonably be expected to cause or result in any stabilization or manipulation of the price of the shares of Common Stock or any reference security with respect to the shares of Common Stock, and
the Company will, and shall cause each of its affiliates to, comply with all applicable provisions of Regulation M. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;<I>Warrant Shares Reserved</I>. The Company shall, at all times while any <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant
Shares upon exercise of such <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of the then-outstanding
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;<I>Reports.</I> During a period of
three years from the date of this Agreement, the Company will furnish to the Representatives, as soon as commercially reasonable after the date they are available, copies of all reports or other communications (financial or other) furnished to
holders of the Offered Securities, and copies of any reports and financial statements furnished to or filed with the Commission or any national securities exchange or automatic quotation system; <U>provided</U> the Company will be deemed to have
furnished such reports and financial statements to the Representatives to the extent they are filed on EDGAR. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;<I>Record Retention</I>. The Company will, pursuant to reasonable procedures developed in good
faith, retain copies of each Issuer Free Writing Prospectus that is not filed with the Commission in accordance with Rule 433 under the Securities Act. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)&nbsp;&nbsp;&nbsp;&nbsp;<I>Shelf Renewal</I>. If immediately prior to the third anniversary (the &#147;Renewal
Deadline&#148;) of the initial effective date of the Registration Statement, any of the Offered Securities remain unsold by the Underwriters, the Company will, prior to the Renewal Deadline, file, if it has not already done so and is eligible to do
so, a new automatic shelf registration statement relating to the Offered Securities, in a form satisfactory to the Representatives. If the Company is not eligible to file an automatic shelf registration statement, the Company will, prior to the
Renewal Deadline, if it has not already done so, file a new shelf registration statement relating to the Offered Securities, in a form satisfactory to the Representatives, and will use its best efforts to cause such registration statement to be
declared effective within 180 days after the Renewal Deadline. The Company will take all other action necessary or appropriate to permit the issuance and sale of the Offered Securities to continue as contemplated in the expired registration
statement relating to the Offered Securities. References herein to the Registration Statement shall include such new automatic shelf registration statement or such new shelf registration statement, as the case may be. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5.&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain Agreements of the Underwriters</U>.&nbsp;&nbsp;&nbsp;&nbsp;Each Underwriter hereby represents and agrees
that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;It has not used, authorized use of, referred to or participated in the planning for use
of, and will not use, authorize use of, refer to or participate in the planning for use of, any &#147;free </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
writing prospectus&#148;, as defined in Rule 405 under the Securities Act (which term includes use of any written information furnished to the Commission by the Company and not incorporated by
reference into the Registration Statement and any press release issued by the Company) other than (i)&nbsp;a free writing prospectus that contains no &#147;issuer information&#148; (as defined in Rule 433(h)(2) under the Securities Act) that was not
included (including through incorporation by reference) in the Preliminary Prospectus or a previously filed Issuer Free Writing Prospectus, (ii)&nbsp;any Issuer Free Writing Prospectus listed on Annex A or prepared pursuant to Section&nbsp;3(c) or
Section&nbsp;4(c) above (including any electronic road show), or (iii)&nbsp;any free writing prospectus prepared by such Underwriter and approved by the Company in advance in writing. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;It has not and will not, without the prior written consent of the Company, use any free writing
prospectus that contains the final terms of the Offered Securities unless such terms have previously been included in a free writing prospectus filed with the Commission; <U>provided</U> that Underwriters may use a term sheet substantially in the
form of Annex B hereto without the consent of the Company; <U>provided</U><I>, </I><U>further</U><I>,</I> that any Underwriter using such term sheet shall notify the Company, and provide a copy of such term sheet to the Company, prior to, or
substantially concurrently with, the first use of such term sheet. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;It is not subject to any
pending proceeding under Section&nbsp;8A of the Securities Act with respect to the offering (and will promptly notify the Company if any such proceeding against it is initiated during the Prospectus Delivery Period). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6.&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditions of Underwriters&#146; Obligations.</U> The obligation of each Underwriter to purchase the Offered
Securities on the Closing Date, as provided herein is subject to the performance by the Company of its covenants and other obligations hereunder and to the following additional conditions: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Registration Compliance; No Stop Order.</I> No order suspending the effectiveness of the
Registration Statement shall be in effect, and no proceeding for such purpose or pursuant to Section&nbsp;8A under the Securities Act shall be pending before or threatened by the Commission; the Prospectus and each Issuer Free Writing Prospectus
shall have been timely filed with the Commission under the Securities Act (in the case of an Issuer Free Writing Prospectus, to the extent required by Rule 433 under the Securities Act) and in accordance with Section&nbsp;4(a) hereof; and all
requests by the Commission for additional information shall have been complied with to the reasonable satisfaction of the Representatives. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Representations and Warranties.</I> The representations and warranties of the Company contained
herein shall be true and correct on the date hereof and on and as of the Closing Date; and the statements of the Company and its officers made in any certificates delivered pursuant to this Agreement shall be true and correct on and as of the
Closing Date. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Material Adverse Change.</I> No event or condition of a type described in
Section&nbsp;3(i) hereof shall have occurred or shall exist, which event or condition is not described in the Pricing Disclosure Package (excluding any amendment or supplement thereto) and the Prospectus (excluding any amendment or supplement
thereto) and the effect of which in the judgment of the Representatives makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Offered Securities on the Closing Date on the terms and in the manner contemplated by
this Agreement, the Pricing Disclosure Package and the Prospectus. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<I>Officer&#146;s
Certificate.</I> The Representatives shall have received on and as of the Closing Date a certificate of the chief financial officer or chief accounting officer of the Company and one additional senior executive officer of the Company who is
satisfactory to the </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">
Representatives, on behalf of the Company and not in their individual capacities, (i)&nbsp;confirming that such officers have carefully reviewed the Registration Statement, the Pricing Disclosure
Package and the Prospectus and, to the knowledge of such officers, the representations set forth in Sections 3(b) and 3(f) hereof are true and correct, (ii)&nbsp;confirming that the other representations and warranties of the Company in this
Agreement are true and correct and that the Company has complied in all material respects with all agreements and satisfied all conditions on its part to be performed or satisfied hereunder at or prior to the Closing Date, and (iii)&nbsp;to the
effect set forth in paragraphs (a), (b) and (c)&nbsp;above. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<I>Comfort Letters.</I> On the date
of this Agreement and on the Closing Date, KPMG LLP shall have furnished to the Representatives, at the request of the Company, letters, dated the respective dates of delivery thereof and addressed to the Underwriters, in form and substance
reasonably satisfactory to the Representatives, containing statements and information of the type customarily included in accountants&#146; &#147;comfort letters&#148; to underwriters with respect to the financial statements and certain financial
information contained or incorporated by reference in each of the Registration Statement, the Pricing Disclosure Package and the Prospectus; <U>provided</U>, that the letter delivered on the Closing Date, shall use a
<FONT STYLE="white-space:nowrap">&#147;cut-off&#148;</FONT> date no more than three business days prior to such Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<I>Opinion and Negative Assurance Letter of Counsel for the Company.</I> Cooley LLP, counsel for the
Company, shall have furnished to the Representatives, at the request of the Company, their written opinion and negative assurance letter, dated the Closing Date, and addressed to the Underwriters, in form and substance reasonably satisfactory to the
Representatives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<I>Opinion of Intellectual Property Counsel for the Company</I>. Foley Hoag
LLP, intellectual property counsel for the Company, shall have furnished to the Representatives, at the request of the Company, their written opinion, dated the Closing Date, and addressed to the Underwriters, in form and substance reasonably
satisfactory to the Representatives. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<I>Opinion and Negative Assurance Letter of Counsel for
the Underwriters.</I> The Representatives shall have received on and as of the Closing Date, an opinion and negative assurance letter of Latham&nbsp;&amp; Watkins LLP, counsel for the Underwriters, with respect to such matters as the Representatives
may reasonably request, and such counsel shall have received such documents and information as they may reasonably request to enable them to pass upon such matters. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<I>No Legal Impediment to Issuance and Sale.</I> No action shall have been taken and no statute,
rule, regulation or order shall have been enacted, adopted or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date, prevent the issuance or sale of the Offered Securities; and no injunction
or order of any federal, state or foreign court shall have been issued that would, as of the Closing Date prevent the issuance or sale of the Offered Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j)&nbsp;&nbsp;&nbsp;&nbsp;<I>Good Standing</I>. The Representatives shall have received on and as of the Closing Date
satisfactory evidence of the good standing of the Company and its subsidiaries in their respective jurisdictions of organization and their good standing as foreign entities in such other jurisdictions as the Representatives may reasonably request,
in each case in writing or any standard form of telecommunication from the appropriate governmental authorities of such jurisdictions. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k)&nbsp;&nbsp;&nbsp;&nbsp;<I>Exchange Listing.</I> Prior to the Closing
Date, the Company shall have filed a Listing of Additional Shares Notification Form with Nasdaq with respect to the Offered Securities. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l)&nbsp;&nbsp;&nbsp;&nbsp;<I><FONT STYLE="white-space:nowrap">Lock-up</FONT> Agreements</I>. The <FONT
STYLE="white-space:nowrap">Lock-Up</FONT> Agreements, each substantially in the form of Exhibit A hereto, between you and the officers, directors and certain securityholders of the Company relating to sales and certain other dispositions of shares
of Stock or certain other securities, delivered to you on or before the date hereof, shall be full force and effect on the Closing Date. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m)&nbsp;&nbsp;&nbsp;&nbsp;<I>[Reserved.]</I> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(n)<I></I>&nbsp;&nbsp;&nbsp;&nbsp;<I>Additional Documents.</I> On or prior to the Closing Date as the case may be, the Company
shall have furnished to the Representatives such further certificates and documents as the Representatives may reasonably request. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All
opinions, letters, certificates and evidence mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form and substance reasonably satisfactory to counsel for the
Underwriters. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7.&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification and Contribution</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Indemnification of the Underwriters.</I> The Company agrees to indemnify and hold harmless each Underwriter, its
affiliates, directors and officers and each person, if any, who controls such Underwriter within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the Exchange Act, from and against any and all losses, claims, damages and
liabilities (including, without limitation, reasonable and documented legal fees and other reasonable and documented expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are incurred),
joint or several, that arise out of, or are based upon, (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Registration Statement or caused by any omission or alleged omission to state therein a material
fact required to be stated therein or necessary in order to make the statements therein, not misleading, or (ii)&nbsp;any untrue statement or alleged untrue statement of a material fact contained in the Prospectus (or any amendment or supplement
thereto), any preliminary prospectus, any Issuer Free Writing Prospectus, any &#147;issuer information&#148; filed or required to be filed pursuant to Rule 433(d) under the Securities Act, any Written <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, any road show as defined in Rule 433(h) under the Securities Act (a &#147;road show&#148;) or any Pricing Disclosure Package (including any Pricing Disclosure Package that
has subsequently been amended), or caused by any omission or alleged omission to state therein a material fact necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading, in each case
except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to any
Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use therein, it being understood and agreed that the only such information furnished by any Underwriter consists of the information
described as such in subsection (b)&nbsp;below. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Indemnification of the Company.</I> Each Underwriter agrees,
severally and not jointly, to indemnify and hold harmless the Company, its directors, its officers who signed the Registration Statement and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the Securities Act or
Section&nbsp;20 of the Exchange Act to the same extent as the indemnity set forth in paragraph (a)&nbsp;above, but only with respect to any losses, claims, damages or liabilities that arise out of, or are based upon, any untrue statement or omission
or alleged untrue statement or omission made in reliance upon and in conformity with any information relating to such Underwriter furnished to the Company in writing by such Underwriter through the Representatives expressly for use in the
Registration Statement, the Prospectus (or any amendment or supplement thereto), any preliminary prospectus, any Issuer Free Writing Prospectus, any Written
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">Testing-the-Waters</FONT></FONT> Communication, any road show or any Pricing Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), it being
understood and agreed upon that the only such information furnished by any Underwriter consists of the following information in the Prospectus furnished on behalf of each Underwriter: the statements set forth in the first sentence of the third and
fourth paragraphs under the caption &#147;Underwriting,&#148; the first two sentences of the first paragraph under the section entitled &#147;Commission and Expenses,&#148; and the first sentence of the first paragraph under the section entitled
&#147;Stabilization,&#148; each under the caption &#147;Underwriting&#148; in the Prospectus Supplement. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>Notice and Procedures.</I> If any suit, action, proceeding (including any governmental or regulatory
investigation), claim or demand shall be brought or asserted against any person in respect of which indemnification may be sought pursuant to the preceding paragraphs of this Section&nbsp;7, such person (the &#147;Indemnified Person&#148;) shall
promptly notify the person against whom such indemnification may be sought (the &#147;Indemnifying Person&#148;) in writing; <U>provided</U> that the failure to notify the Indemnifying Person shall not relieve it from any liability that it may have
under the preceding paragraphs of this Section&nbsp;7 except to the extent that it has been materially prejudiced (through the forfeiture of substantive rights or defenses) by such failure; and <U>provided</U>, <U>further</U>, that the failure to
notify the Indemnifying Person shall not relieve it from any liability that it may have to an Indemnified Person otherwise than under the preceding paragraphs of this Section&nbsp;7. If any such proceeding shall be brought or asserted against an
Indemnified Person and it shall have notified the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall not, without the consent of the Indemnified Person, be counsel
to the Indemnifying Person) to represent the Indemnified Person and any others entitled to indemnification pursuant to this Section that the Indemnifying Person may designate in such proceeding and shall pay the reasonable and documented fees and
expenses in such proceeding and shall pay the reasonable and documented fees and expenses of such counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified Person shall have the right to retain its own counsel, but the
fees and expenses of such counsel shall be at the expense of such Indemnified Person unless (i)&nbsp;the Indemnifying Person and the Indemnified Person shall have mutually agreed to the contrary; (ii)&nbsp;the Indemnifying Person has failed within a
reasonable time to retain counsel reasonably satisfactory to the Indemnified Person; (iii)&nbsp;the Indemnified Person shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition to those
available to the Indemnifying Person; or (iv)&nbsp;the named parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified Person and representation of both parties by the same counsel
would be inappropriate due to actual or potential differing interests between them. It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceeding in the same jurisdiction, be liable for
the fees and expenses of more than one separate firm (in addition to any local counsel) for all Indemnified Persons, and that all such fees and expenses shall be paid or reimbursed as they are incurred. Any such separate firm for any Underwriter,
its affiliates, directors and officers and any control persons of such Underwriter shall be designated in writing by the Representatives and any such </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
separate firm for the Company, its directors, its officers who signed the Registration Statement and any control persons of the Company shall be designated in writing by the Company. The
Indemnifying Person shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent, the Indemnifying Person agrees to indemnify each Indemnified Person from and against any loss or
liability by reason of such settlement. Notwithstanding the foregoing sentence, if at any time an Indemnified Person shall have requested that an Indemnifying Person reimburse the Indemnified Person for fees and expenses of counsel as contemplated
by this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding effected without its written consent if (i)&nbsp;such settlement is entered into more than 30 days after receipt by the Indemnifying Person of such
request and (ii)&nbsp;the Indemnifying Person shall not have reimbursed the Indemnified Person in accordance with such request prior to the date of such settlement. No Indemnifying Person shall, without the written consent of the Indemnified Person,
effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnification could have been sought hereunder by such Indemnified Person, unless such settlement
(x)&nbsp;includes an unconditional release of such Indemnified Person, in form and substance reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject matter of such proceeding and (y)&nbsp;does not
include any statement as to or any admission of fault, culpability or a failure to act by or on behalf of any Indemnified Person. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<I>Contribution.</I> If the indemnification provided for in paragraphs (a)&nbsp;or (b) above is unavailable to an
Indemnified Person or insufficient in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu of indemnifying such Indemnified Person thereunder, shall contribute to the
amount paid or payable by such Indemnified Person as a result of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received by the Company, on the one hand, and the
Underwriters on the other, from the offering of the Offered Securities or (ii)&nbsp;if the allocation provided by clause (i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits
referred to in clause (i)&nbsp;but also the relative fault of the Company, on the one hand, and the Underwriters on the other, in connection with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as
any other relevant equitable considerations. The relative benefits received by the Company, on the one hand, and the Underwriters on the other, shall be deemed to be in the same respective proportions as the net proceeds (before deducting expenses)
received by the Company from the sale of the Offered Securities and the total underwriting discounts and commissions received by the Underwriters in connection therewith, in each case as set forth in the table on the cover of the Prospectus, bear to
the aggregate offering price of the Offered Securities. The relative fault of the Company, on the one hand, and the Underwriters on the other, shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of
a material fact or the omission or alleged omission to state a material fact relates to information supplied by the Company or by the Underwriters and the parties&#146; relative intent, knowledge, access to information and opportunity to correct or
prevent such statement or omission. </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<I>Limitation on Liability.</I> The Company and the Underwriters agree that
it would not be just and equitable if contribution pursuant to paragraph (d)&nbsp;above were determined by <U>pro</U> <U>rata</U> allocation (even if the Underwriters were treated as one entity for such purpose) or by any other method of allocation
that does not take account of the equitable considerations referred to in paragraph (d)&nbsp;above. The amount paid or payable by an Indemnified Person as a result of the losses, claims, damages and liabilities referred to in paragraph
(d)&nbsp;above shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such Indemnified Person in connection with any such action or claim. Notwithstanding the provisions of
paragraphs (d)&nbsp;and (e), in no event shall an Underwriter be required to contribute any amount in excess of the amount by which the total underwriting discounts and commissions received by such Underwriter with respect to the offering of the
Offered Securities exceeds the amount of any damages that such Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No person guilty of fraudulent
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
misrepresentation (within the meaning of Section&nbsp;11(f) of the Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation. The
Underwriters&#146; obligations to contribute pursuant to paragraphs (d)&nbsp;and (e) are several in proportion to their respective purchase obligations hereunder and not joint. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<I><FONT STYLE="white-space:nowrap">Non-Exclusive</FONT> Remedies.</I> The remedies provided for in this
Section&nbsp;7 are not exclusive and shall not limit any rights or remedies which may otherwise be available to any Indemnified Person at law or in equity. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8.&nbsp;&nbsp;&nbsp;&nbsp;<U>Effectiveness of Agreement</U>. This Agreement shall become effective as of the date first written above. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9.&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>. This Agreement may be terminated in the absolute discretion of the Representatives, by notice to
the Company, if after the execution and delivery of this Agreement and prior to the Closing Date: (i)&nbsp;trading generally shall have been suspended or materially limited on or by any of the New York Stock Exchange or The Nasdaq Stock Market;
(ii)&nbsp;trading of any securities issued or guaranteed by the Company shall have been suspended on any exchange or in any <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market; (iii)&nbsp;a general
moratorium on commercial banking activities shall have been declared by federal or New York State authorities; or (v)&nbsp;there shall have occurred any outbreak or escalation of hostilities or any change in financial markets or any calamity or
crisis, either within or outside the United States, that, in the judgment of the Representatives, is material and adverse and makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Offered Securities on the
Closing Date on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">10.&nbsp;&nbsp;&nbsp;&nbsp;<U>Defaulting Underwriter</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;If, on the Closing Date any Underwriter defaults on its obligation to purchase the Offered Securities that it has
agreed to purchase hereunder on such date, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters may in their discretion arrange for the purchase of such Offered Securities by other persons satisfactory to the Company on the terms
contained in this Agreement. If, within 36 hours after any such default by any Underwriter, the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters do not arrange for the purchase of such Offered Securities, then the Company shall be
entitled to a further period of 36 hours within which to procure other persons satisfactory to the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters to purchase such Offered Securities on such terms. If other persons become
obligated or agree to purchase the Offered Securities of a defaulting Underwriter, either the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters or the Company may postpone the Closing Date for up to five full business days in order
to effect any changes that in the opinion of counsel for the Company or counsel for the Underwriters may be necessary in the Registration Statement and the Prospectus or in any other document or arrangement, and the Company agrees to promptly
prepare any amendment or supplement to the Registration Statement and the Prospectus that effects any such changes. As used in this Agreement, the term &#147;Underwriter&#148; includes, for all purposes of this Agreement unless the context otherwise
requires, any person not listed in Schedule 1 hereto that, pursuant to this Section&nbsp;10, purchases Offered Securities that a defaulting Underwriter agreed but failed to purchase. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;If, after giving effect to any arrangements for the purchase of the Offered Securities of a defaulting Underwriter
or Underwriters by the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of Offered Securities that remain unpurchased on the Closing Date does not
exceed <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate number of Offered Securities to be purchased on such date, then the Company shall have the right to require each <FONT STYLE="white-space:nowrap">non-defaulting</FONT>
Underwriter to purchase the number of Offered Securities that such Underwriter agreed to purchase hereunder on such date plus such Underwriter&#146;s pro rata share (based on the number of Offered Securities that such Underwriter agreed to purchase
on such date) of the Offered Securities of such defaulting Underwriter or Underwriters for which such arrangements have not been made. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;If, after giving effect to any arrangements for the purchase of
the Offered Securities of a defaulting Underwriter or Underwriters by the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters and the Company as provided in paragraph (a)&nbsp;above, the aggregate number of Offered Securities that
remain unpurchased on the Closing Date exceeds <FONT STYLE="white-space:nowrap">one-eleventh</FONT> of the aggregate amount of Offered Securities to be purchased on such date, or if the Company shall not exercise the right described in paragraph
(b)&nbsp;above, then this Agreement shall terminate without liability on the part of the <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriters. Any termination of this Agreement pursuant to this Section&nbsp;10 shall be without
liability on the part of the Company, except that the Company will continue to be liable for the payment of expenses as set forth in Section&nbsp;11 hereof and except that the provisions of Section&nbsp;7 hereof shall not terminate and shall remain
in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;Nothing contained herein shall relieve a defaulting Underwriter of any liability it may have to the
Company or any <FONT STYLE="white-space:nowrap">non-defaulting</FONT> Underwriter for damages caused by its default. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">11.&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment of Expenses</U><I>.</I> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;Whether or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the
Company will pay or cause to be paid all costs and expenses incident to the performance of its obligations hereunder, including without limitation, (i)&nbsp;the costs incident to the authorization, issuance, sale, preparation and delivery of the
Offered Securities and any taxes payable in that connection; (ii)&nbsp;the costs incident to the preparation, printing and filing under the Securities Act of the Registration Statement, any preliminary prospectus, any Issuer Free Writing Prospectus,
any Pricing Disclosure Package and the Prospectus (including all exhibits, amendments and supplements thereto) and the distribution thereof; (iii)&nbsp;the fees and expenses of the Company&#146;s counsel and independent accountants; (iv)&nbsp;the
fees and expenses incurred in connection with the registration or qualification and determination of eligibility for investment of the Offered Securities under the state or foreign securities or blue sky laws of such jurisdictions as the
Representatives may designate and the preparation, printing and distribution of a Blue Sky Memorandum and any &#147;Canadian wrapper&#148; (including the related and documented fees and expenses of counsel for the Underwriters);&nbsp;(v) the cost of
preparing stock certificates, if applicable; (vi)&nbsp;the costs and charges of any transfer agent and any registrar; (vii)&nbsp;all expenses and application fees incurred in connection with any filing with, and clearance of the offering by, FINRA
(including the related and documented fees and expenses of counsel for the Underwriters), <U>provided</U> that the fees and expenses pursuant to clauses (iv)&nbsp;and (vii) shall not, in the aggregate, exceed $35,000; (viii) all expenses incurred by
the Company in connection with any &#147;road show&#148; presentation to potential investors (<U>provided</U> that subject to the Company&#146;s and Representatives&#146; prior written approval of each such expense, the cost of any chartered plane
to be used in connection with any &#147;road show&#148; presentation to potential investors will be paid 50% by the Company and 50% by the Underwriters); and (ix)&nbsp;all expenses and application fees related to the listing of the Offered
Securities on the Nasdaq Global Select Market. It is understood, however, that except as provided in this Section&nbsp;11 or Section&nbsp;7 hereof, the Underwriters will pay their own costs and expenses, including the fees of their counsel, stock
transfer taxes on the resale of any of the Offered Securities owned by them, any advertising expenses connected with any offers they may make and all travel (except as set forth in clause (viii)&nbsp;above), lodging and other expenses of the
Underwriters, any of their employees, their representatives and counsel. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;If (i)&nbsp;this Agreement is
terminated pursuant to Section&nbsp;9, (ii) the Company for any reason fails to tender the Offered Securities for delivery to the Underwriters or (iii)&nbsp;the Underwriters decline to purchase the Offered Securities for any reason permitted under
this Agreement, the Company agrees to reimburse the Underwriters for all documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs and expenses (including the fees and expenses of their counsel)
reasonably incurred by the Underwriters in connection with this Agreement and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the offering contemplated hereby; <U>provided</U>, however, that for purposes of this Section&nbsp;11(b), the Company shall in no event be liable to any of the Underwriters for any other amounts
(for the avoidance of doubt, not including any amounts under Section&nbsp;7 hereof), including, without limitation, damages on account of loss of anticipated profits from the sale of the Offered Securities. For the avoidance of doubt, it is
understood that the Company shall not pay or reimburse any costs, fees or expenses incurred by any Underwriter that defaults on its obligations to purchase the Offered Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">12.&nbsp;&nbsp;&nbsp;&nbsp;<U>Persons Entitled to Benefit of Agreement</U>. This Agreement shall inure to the benefit of and be binding upon
the parties hereto and their respective successors and the officers and directors and any controlling persons referred to herein, and the affiliates of each Underwriter referred to in Section&nbsp;7 hereof. Nothing in this Agreement is intended or
shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement or any provision contained herein. No purchaser of Offered Securities from any Underwriter shall be deemed to be a
successor merely by reason of such purchase. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">13.&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>. The respective indemnities, rights of
contribution, representations, warranties and agreements of the Company and the Underwriters contained in this Agreement or made by or on behalf of the Company or the Underwriters pursuant to this Agreement or any certificate delivered pursuant
hereto shall survive the delivery of and payment for the Offered Securities and shall remain in full force and effect, regardless of any termination of this Agreement or any investigation made by or on behalf of the Company or the Underwriters or
the directors, officers, controlling persons or affiliates referred to in Section&nbsp;7 hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">14.&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Defined Terms</U>. For purposes of this Agreement, (a)&nbsp;except where otherwise expressly provided, the term &#147;affiliate&#148; has the meaning set forth in Rule 405 under the Securities Act; (b)&nbsp;the term &#147;business day&#148; means
any day other than a day on which banks are permitted or required to be closed in New York City; (c)&nbsp;the term &#147;subsidiary&#148; has the meaning set forth in Rule 405 under the Securities Act; and (d)&nbsp;the term &#147;significant
subsidiary&#148; has the meaning set forth in Rule <FONT STYLE="white-space:nowrap">1-02</FONT> of Regulation <FONT STYLE="white-space:nowrap">S-X</FONT> under the Exchange Act. In the event that the Company has only one subsidiary, then all
references herein to &#147;subsidiaries&#148; of the Company shall be deemed to refer to such single subsidiary, mutatis mutandis. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">15.&nbsp;&nbsp;&nbsp;&nbsp;<U>Compliance with USA Patriot Act</U>. In accordance with the requirements of the USA Patriot Act (Title III of
Pub. L. <FONT STYLE="white-space:nowrap">107-56</FONT> (signed into law October&nbsp;26, 2001)), the Underwriters are required to obtain, verify and record information that identifies their respective clients, including the Company, which
information may include the name and address of their respective clients, as well as other information that will allow the Underwriters to properly identify their respective clients. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">16.&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&nbsp;&nbsp;&nbsp;&nbsp;<I>Notices.</I> All notices and other communications hereunder shall be in writing and shall be
deemed to have been duly given if mailed or transmitted and confirmed by any standard form of telecommunication. Notices to the Underwriters shall be given to the Representatives c/o Jefferies LLC, 520 Madison Avenue, New York, New York 10022,
Attention: General Counsel and c/o Cowen and Company, LLC, 599 Lexington Avenue, New York, New York 10022, Attention: Head of Equity Capital Markets, Fax: <FONT STYLE="white-space:nowrap">646-562,1249</FONT> with a copy to the General Counsel.
Notices to the Company shall be given to it at Annexon, Inc., 1400 Sierra Point Parkway, Bldg C, Suite 200, Brisbane, California 94005; Attention: Chief Financial Officer <FONT STYLE="white-space:nowrap">(e-mail:</FONT> jlew@annexonbio.com), with a
copy (which shall not constitute notice) to Cooley LLP, 55 Hudson Yards, New York, New York 10001, Attention: Divakar Gupta, Charles S. Kim. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&nbsp;&nbsp;&nbsp;&nbsp;<I>Governing Law.</I> This Agreement and any claim, controversy
or dispute arising under or related to this Agreement shall be governed by and construed in accordance with the laws of the State of New York. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&nbsp;&nbsp;&nbsp;&nbsp;<I>Submission to Jurisdiction</I>. The Company hereby submits to the exclusive jurisdiction of the U.S. federal and
New York state courts in the Borough of Manhattan in The City of New York in any suit or proceeding arising out of or relating to this Agreement or the transactions contemplated hereby. The Company waives any objection which it may now or hereafter
have to the laying of venue of any such suit or proceeding in such courts. The Company agrees that final judgment in any such suit, action or proceeding brought in such court shall be conclusive and binding upon the Company and may be enforced in
any court to the jurisdiction of which Company is subject by a suit upon such judgment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&nbsp;&nbsp;&nbsp;&nbsp;<I>Waiver of Jury
Trial</I>. Each of the parties hereto waives, to the fullest extent permitted by applicable law, any and all right to trial by jury in any suit or legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)&nbsp;&nbsp;&nbsp;&nbsp;<I>Recognition of the U.S. Special Resolution Regimes</I>. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) In the event that any Underwriter that is a Covered Entity becomes subject to a proceeding under a U.S. Special Resolution
Regime, the transfer from such Underwriter of this Agreement, and any interest and obligation in or under this Agreement, will be effective to the same extent as the transfer would be effective under the U.S. Special Resolution Regime if this
Agreement, and any such interest and obligation, were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) In the event that any Underwriter that is a Covered Entity or a BHC Act Affiliate of such Underwriter becomes subject to a
proceeding under a U.S. Special Resolution Regime, Default Rights under this Agreement that may be exercised against such Underwriter are permitted to be exercised to no greater extent than such Default Rights could be exercised under the U.S.
Special Resolution Regime if this Agreement were governed by the laws of the United States or a state of the United States. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">As used in this Section&nbsp;16(e): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;BHC Act Affiliate&#148; has the meaning assigned to the term &#147;affiliate&#148; in, and shall be interpreted in
accordance with, 12 U.S.C. &#167; 1841(k). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Covered Entity&#148; means any of the following: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) a &#147;covered entity&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 252.82(b);
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) a &#147;covered bank&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167; 47.3(b);
or </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) a &#147;covered FSI&#148; as that term is defined in, and interpreted in accordance with, 12 C.F.R. &#167;
382.2(b). </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;Default Right&#148; has the meaning assigned to that term in, and shall be interpreted in accordance with, 12 C.F.R.
&#167;&#167; 252.81, 47.2 or 382.1, as applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">&#147;U.S. Special Resolution Regime&#148; means each of (i)&nbsp;the Federal Deposit
Insurance Act and the regulations promulgated thereunder and (ii)&nbsp;Title II of the Dodd-Frank Wall Street Reform and Consumer Protection Act and the regulations promulgated thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)&nbsp;&nbsp;&nbsp;&nbsp;<I>Counterparts.</I> This Agreement may be signed in counterparts (which may include counterparts delivered by any
standard form of telecommunication), each of which shall be an original and all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including any electronic signature covered
by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to
have been duly and validly delivered and be valid and effective for all purposes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g)&nbsp;&nbsp;&nbsp;&nbsp;<I>Amendments or
Waivers.</I> No amendment or waiver of any provision of this Agreement, nor any consent or approval to any departure therefrom, shall in any event be effective unless the same shall be in writing and signed by the parties hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)&nbsp;&nbsp;&nbsp;&nbsp;<I>Headings.</I> The headings herein are included for convenience of reference only and are not intended to be part
of, or to affect the meaning or interpretation of, this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i)&nbsp;&nbsp;&nbsp;&nbsp;<I>Integration. </I>This Agreement
supersedes all prior agreements and understandings (whether written or oral) between the Company and the Underwriters, or any of them, with respect to the subject matter hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page Follows] </I></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the foregoing is in accordance with your understanding, please indicate your acceptance
of this Agreement by signing in the space provided below. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="11%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Very&nbsp;truly&nbsp;yours,</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">ANNEXON, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">By:&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Douglas Love</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Douglas Love, Esq.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: President and Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Accepted: As of the date first written above </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">JEFFERIES LLC </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">COWEN AND COMPANY, LLC </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For themselves and on behalf of the </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">several Underwriters listed
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">in Schedule 1 hereto. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">JEFFERIES LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">B<SMALL>Y</SMALL>:&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Dustin Tyner</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Authorized Signatory</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16" COLSPAN="3"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">COWEN AND COMPANY, LLC</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">B<SMALL>Y</SMALL>:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Bill Follis</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="center">Authorized Signatory</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to the Underwriting Agreement] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Schedule 1 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; ">Underwriter</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Number of Offered Shares</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; " ALIGN="center">Number of
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants</P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jefferies LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">13,456,313</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">9,879,175</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cowen and Company, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">11,578,687</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">8,500,686</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">25,035,000</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP ALIGN="right"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">18,379,861</P></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex A </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">a.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Pricing Disclosure Package</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Free Writing Prospectus dated December&nbsp;20, 2023. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">b.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left"><B>Pricing Information</B> </P></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Number of Offered Shares: 25,035,000 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Number of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants: 18,379,861 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Price per share of Common Stock to the public: $2.880 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Price per <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant to the public: $2.879 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Terms of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants: <FONT STYLE="white-space:nowrap">Pre-funded</FONT> Warrants to purchase
18,379,861&nbsp;shares of the Company&#146;s Common Stock are being offered to certain existing large investors in lieu of shares of Common Stock. Each <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant will entitle the holder thereof to
purchase one (1)&nbsp;share of the Company&#146;s Common Stock, will have an exercise price of $0.001 per share, will be exercisable upon issuance and will not expire. In general, a holder will not have the right to exercise any portion of the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant if the holder (together with its affiliates) would beneficially own in excess of 9.99% of the number of shares of the Company&#146;s Common Stock outstanding immediately after giving effect to the
exercise, as such percentage ownership is determined in accordance with the terms of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Annex B </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Annexon, Inc. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><U>Pricing Term
Sheet</U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">None. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right">Exhibit A </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">FORM OF <FONT STYLE="white-space:nowrap">LOCK-UP</FONT> AGREEMENT </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[<I>Under separate cover</I>] </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>3
<FILENAME>d456025dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;<B>SECURITIES ACT</B>&#148;). THE HOLDER
MAY NOT OFFER, SELL, TRANSFER, ASSIGN, PLEDGE, HYPOTHECATE, OR OTHERWISE DISPOSE OF OR ENCUMBER SUCH SECURITIES EXCEPT (I)&nbsp;PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT OR PROSPECTUS UNDER THE SECURITIES ACT AND THE RULES AND REGULATIONS
PROMULGATED THEREUNDER AND IN COMPLIANCE WITH ANY APPLICABLE STATE SECURITIES LAW, RESPECTIVELY, OR WITH AN EXEMPTION FROM SUCH REGISTRATION OR PROSPECTUS REQUIREMENT AND (II)&nbsp;IN COMPLIANCE WITH THAT CERTAIN UNDERWRITING AGREEMENT, DATED
DECEMBER&nbsp;20, 2023, AMONG THE ISSUER AND THE UNDERWRITERS PARTY THERETO. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ANNEXON, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANT TO PURCHASE COMMON STOCK </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Number of Shares: [&#149;]</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">(subject to adjustment)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Warrant No. [&#149;]</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Original Issue Date: December&nbsp;20, 2023</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annexon, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), hereby certifies that, for good and valuable
consideration, the receipt and sufficiency of which are hereby acknowledged, [&#149;] or its registered assigns (the &#147;<B>Holder</B>&#148;), is entitled, subject to the terms set forth below, to purchase from the Company up to a total of
[&#149;] shares of common stock, $0.001 par value per share (the &#147;<B>Common Stock</B>&#148;), of the Company (each such share, a &#147;<B>Warrant Share</B>&#148; and all such shares, the &#147;<B>Warrant Shares</B>&#148;) at an exercise price
per share equal to $0.001 per share (as adjusted from time to time as provided in <U>Section</U><U></U><U>&nbsp;9</U> herein, the &#147;<B>Exercise Price</B>&#148;), upon surrender of this Warrant to Purchase Common Stock (including any Warrants to
Purchase Common Stock issued in exchange, transfer or replacement hereof, the &#147;<B>Warrant</B>&#148;) at any time and from time to time on or after the date hereof (the &#147;<B>Original Issue Date</B>&#148;), subject to the following terms and
conditions: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <I>Definitions</I>. For purposes of this Warrant, the following terms shall have the following meanings: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>Affiliate</B>&#148; means any Person directly or indirectly controlled by, controlling or under common control with, a Holder, as
such terms are used in and construed under Rule 405 under the Securities Act, but only for so long as such control shall continue. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)
&#147;<B>Commission</B>&#148; means the United States Securities and Exchange Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Closing Sale Price</B>&#148;
means, for any security as of any date, the last trade price for such security on the Principal Trading Market for such security, as reported by Bloomberg L.P., or, if such Principal Trading Market begins to operate on an extended hours basis and
does not designate the last trade price, then the last trade price of such security prior to 4:00 P.M., New York City time, as reported by Bloomberg L.P., or if the security is not listed for trading on a national securities exchange or other
trading market on the relevant date, the last quoted bid price for the security in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the relevant date as reported by OTC Markets
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Group Inc. (or a similar organization or agency succeeding to its functions of reporting prices). If the Closing Sale Price cannot be calculated for a security on a particular date on any of the
foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security,
then the Board of Directors of the Company shall use its good faith judgment to determine the fair market value. The Board of Directors&#146; determination shall be binding upon all parties absent demonstrable error. All such determinations shall be
appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Principal Trading Market</B>&#148; means the national securities exchange or other trading market on which the Common Stock is
primarily listed on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global Select Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e)
&#147;<B>Securities Act</B>&#148; means the Securities Act of 1933, as amended. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B>Standard Settlement Period</B>&#148; means
the standard settlement period, expressed in a number of Trading Days, for the Company&#146;s Principal Trading Market or quotations system with respect to the Common Stock that is in effect on the date of delivery of an applicable Exercise Notice,
which as of the Original Issue Date was &#147;T+2.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) &#147;<B>Trading Day</B>&#148; means any weekday on which the Principal
Trading Market is open for trading. If the Common Stock is not listed or admitted for trading, &#147;<B>Trading Day</B>&#148; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day on
which banking institutions in New York City are authorized or required by law or other governmental action to close. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)
&#147;<B>Transfer Agent</B>&#148; means Computershare, Inc., the Company&#146;s transfer agent and registrar for the Common Stock, and any successor appointed in such capacity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) &#147;<B>Warrant Share Registration Statement</B>&#148; means the Company&#146;s new Registration Statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> to be filed with the Securities and Exchange Commission to register the resale of the Warrant Shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2.
<I>Issuance of Securities; Registration of Warrants</I>. The Warrant, as initially issued by the Company, is offered and sold pursuant to a private placement without being registered under the Securities Act and the rules and regulations of the
Commission thereunder, in reliance upon Section&nbsp;4(a)(2) thereof and/or Regulation D thereunder. The Warrant Shares will be registered pursuant to the Warrant Share Registration Statement. Accordingly, until the Warrant Share Registration
Statement is declared effective, the Warrant Shares are &#147;restricted securities&#148; under Rule 144 promulgated under the Securities Act (&#147;<B>Rule 144</B>&#148;). The Company shall register ownership of this Warrant, upon records to be
maintained by the Company for that purpose (the &#147;<B>Warrant Register</B>&#148;), in the name of the record Holder (which shall include the initial Holder or, as the case may be, any assignee to which this Warrant is assigned hereunder) from
time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other purposes, absent actual notice to the
contrary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <I>Registration of Transfers</I>. Subject to compliance with all applicable securities laws and the rules
of the Principal Trading Market, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer
taxes (if any), and (x)&nbsp;delivery, at the request of the Company, of an opinion of counsel reasonably satisfactory to the Company to the effect that the transfer of such portion of this Warrant may be made pursuant to an available exemption from
the registration requirements of the Securities Act and all applicable state securities or blue sky laws (other than in connection with any transfer (i)&nbsp;pursuant to an effective registration statement, (ii)&nbsp;to the Company or
(iii)&nbsp;pursuant to Rule 144), and (y)&nbsp;delivery by the transferee of a written statement to the Company certifying that the transferee is an &#147;accredited investor&#148; as defined in Rule 501(a) under the Securities Act. Upon any such
registration or transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a &#147;<B>New Warrant</B>&#148;) evidencing the portion of this Warrant so transferred shall be issued to the
transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such
transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the Company&#146;s own expense any
New Warrant under this <U>Section</U><U></U><U>&nbsp;3</U>. Until due presentment for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder for all purposes, and the Company shall not be affected by any
notice to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <I>Exercise and Duration of Warrants</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) All or any part of this Warrant shall be exercisable by the registered Holder in any manner permitted by this Warrant at any time and from
time to time on or after the Original Issue Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Holder may exercise this Warrant by delivering to the Company (i)&nbsp;an
exercise notice, in the form attached as <U>Schedule 1</U> hereto (the &#147;<B>Exercise Notice</B>&#148;), completed and duly signed, and (ii)&nbsp;payment of the Exercise Price for the number of Warrant Shares as to which this Warrant is being
exercised (which may take the form of a &#147;cashless exercise&#148; if so indicated in the Exercise Notice pursuant to <U>Section</U><U></U><U>&nbsp;10</U> below). The date on which such exercise notice is delivered to the Company (as determined
in accordance with the notice provisions hereof) is an &#147;<B>Exercise Date.</B>&#148; The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall
have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any. The aggregate exercise price of this Warrant, except for the Exercise Price,
was <FONT STYLE="white-space:nowrap">pre-funded</FONT> to the Company on or before the Original Issue Date, and consequently no additional consideration (other than the Exercise Price) shall be required by to be paid by the Holder to effect any
exercise of this Warrant. The Holder shall not be entitled to the return or refund of all, or any portion, of such <FONT STYLE="white-space:nowrap">pre-funded</FONT> exercise price under any circumstance or for any reason whatsoever. <B>The Holder
and any assignee, by acceptance of this Warrant, acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of Warrant Shares available for purchase
hereunder at any given time may be less than the amount stated on the face hereof.</B> </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <I>Delivery of Warrant Shares</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Upon exercise of this Warrant, provided that the Warrant Share Registration Statement is effective or the Warrant Shares are freely
transferable without restriction under Rule 144, the Company shall promptly (but in no event later than the earlier of (i)&nbsp;two Trading Days and (ii)&nbsp;the number of Trading Days comprising the Standard Settlement Period), upon the request of
the Holder, cause the Transfer Agent to credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such exercise to the Holder&#146;s or its designee&#146;s balance account with The Depository Trust Company
(&#147;<B>DTC</B>&#148;) through its Deposit Withdrawal Agent Commission system, or if the Transfer Agent is not participating in the Fast Automated Securities Transfer Program (the &#147;<B>FAST Program</B>&#148;), a certificate for the Warrant
Shares issuable upon such exercise, free of restrictive legends. If the Warrant Share Registration Statement is not effective or the Warrant Shares are not freely transferable without restriction under Rule 144, such Holder shall receive a
certificate for the Warrant Shares issuable upon such exercise with appropriate restrictive legends, dispatched by overnight courier to the address as specified in the Exercise Notice, registered in the Company&#146;s share register in the name of
the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled pursuant to such exercise. The Holder, or any natural person or legal entity (each, a &#147;<B>Person</B>&#148;) so designated by the Holder to
receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such Warrant Shares are credited to the Holder&#146;s DTC account or the date of delivery of the
certificates evidencing such Warrant Shares, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If by the time frames set forth for delivery above, the Company
fails to deliver to the Holder a certificate representing the required number of Warrant Shares in the manner required pursuant to <U>Section</U><U></U><U>&nbsp;5(a)</U> or fails to cause the Transfer Agent to credit the Holder&#146;s DTC account
for such number of Warrant Shares to which the Holder is entitled, and if after such time frame set forth for delivery above and prior to the receipt of such Warrant Shares, the Holder purchases (in an open market transaction or otherwise,
<I>provided</I> such purchases shall be made in a commercially reasonable manner at prevailing market prices) shares of Common Stock to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon
such exercise (a &#147;<B>Buy</B><B><FONT STYLE="white-space:nowrap">-In</FONT></B>&#148;), then the Company shall, within two (2)&nbsp;Trading Days after the Holder&#146;s written request (x)&nbsp;pay cash to the Holder in an amount equal to the
excess (if any) of Holder&#146;s total purchase price (including commercially reasonable brokerage commissions, if any) for the shares of Common Stock so purchased in the <FONT STYLE="white-space:nowrap">Buy-In</FONT> (assuming such sale was
executed on commercially reasonable terms at prevailing market prices) over the product of (A)&nbsp;the number of shares of Common Stock purchased in the <FONT STYLE="white-space:nowrap">Buy-In,</FONT> times (B)&nbsp;the Closing Sale Price of a
share of Common Stock on the Exercise Date and (y)&nbsp;at the option of the Holder, either promptly deliver to the Holder a certificate or certificates representing such Warrant Shares or reinstate the portion of the Warrant and equivalent number
of Warrant Shares for which such exercise was not honored (in which case such exercise shall be deemed rescinded). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) To the extent permitted by law and subject to <U>Section</U><U></U><U>&nbsp;5(b)</U>,
the Company&#146;s obligations to cause the Transfer Agent to issue and deliver Warrant Shares in accordance with and subject to the terms hereof (including the limitations set forth in <U>Section</U><U></U><U>&nbsp;11</U> below) are absolute and
unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any setoff,
counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and irrespective
of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Subject to <U>Section</U><U></U><U>&nbsp;5(b)</U>, nothing herein shall limit the Holder&#146;s
right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#146;s failure to timely deliver certificates
representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <I>Charges, Taxes and Expenses</I>.
Issuance and delivery of certificates for shares of Common Stock, if any, upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any
applicable stamp duties) in respect of the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; <I>provided</I>, <I>however</I>, that the Company shall not be required to pay any tax that may be payable in
respect of any transfer involved in the registration of any certificates for Warrant Shares or the Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise
as a result of holding or transferring this Warrant or receiving Warrant Shares upon exercise hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <I>Replacement of Warrant</I>. If this Warrant
is mutilated, lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence
reasonably satisfactory to the Company of such loss, theft or destruction (in such case) and, in each case, a customary and reasonable indemnity and surety bond, if requested by the Company. Applicants for a New Warrant under such circumstances
shall also comply with such other reasonable regulations and procedures and pay such other reasonable <FONT STYLE="white-space:nowrap">third-party</FONT> costs as the Company may prescribe. If a New Warrant is requested as a result of a mutilation
of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition precedent to the Company&#146;s obligation to issue the New Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <I>Reservation of Warrant Shares</I>. The Company covenants that it will, at all times while this Warrant is outstanding, reserve and keep available out of
the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are issuable and
deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking into account the adjustments and restrictions of <U>Section</U><U></U><U>&nbsp;9</U>).
The failure of the Company to reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock a sufficient number of shares of Common Stock to enable it to issue Warrant Shares upon exercise of
this Warrant as herein provided is referred to herein as an &#147;<B>Authorized Share Failure</B>.&#148; The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the applicable Exercise Price
in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> The Company will take all such action as may be reasonably necessary to assure that such shares of
Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
listed. The Company further covenants that it will not, without the prior written consent of the Holder, take any actions to increase the par value of the Common Stock at any time while this
Warrant is outstanding. In furtherance of the Company&#146;s obligations set forth in this Section&nbsp;8, as soon as practicable after the date of the occurrence of an Authorized Share Failure, but in no event later than ninety (90)&nbsp;days after
the occurrence of such Authorized Share Failure, the Company shall hold a meeting of its stockholders for the approval of an increase in the number of authorized shares of Common Stock. In connection with such meeting, the Company shall provide each
stockholder with a proxy statement and shall use its reasonable best efforts to solicit its stockholders&#146; approval of such increase in authorized shares of Common Stock and to cause its board of directors to recommend to the stockholders that
they approve such proposal. Notwithstanding the foregoing, if at any such time of an Authorized Share Failure, the Company is able to obtain the written consent of a majority of the shares of its issued and outstanding shares of Common Stock to
approve the increase in the number of authorized shares of Common Stock, the Company may satisfy this obligation by obtaining such consent and submitting for filing with the Commission an Information Statement on Schedule 14C. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. <I>Certain Adjustments</I>. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to
time as set forth in this <U>Section</U><U></U><U>&nbsp;9</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Stock Dividends and Splits</U>. If the Company, at any time while
this Warrant is outstanding, (i)&nbsp;pays a stock dividend on its Common Stock or otherwise makes a distribution on any class of capital stock issued and outstanding on the Original Issue Date and in accordance with the terms of such stock on the
Original Issue Date or as amended, as described in the Company&#146;s filings with the Commission, that is payable in shares of Common Stock, (ii)&nbsp;subdivides its outstanding shares of Common Stock into a larger number of shares of Common Stock,
(iii)&nbsp;combines its outstanding shares of Common Stock into a smaller number of shares of Common Stock or (iv)&nbsp;issues by reclassification of shares of capital stock any additional shares of Common Stock of the Company, then in each such
case the Exercise Price shall be multiplied by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately before such event and the denominator of which shall be the number of shares of Common Stock
outstanding immediately after such event. Any adjustment made pursuant to clause (i)&nbsp;of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or
distribution, <I>provided</I>, <I>however</I>, that if such record date shall have been fixed and such dividend is not fully paid on the date fixed therefor, the Exercise Price shall be recomputed accordingly as of the close of business on such
record date and thereafter the Exercise Price shall be adjusted pursuant to this paragraph as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii)&nbsp;or (iii) of this paragraph shall become effective immediately
after the effective date of such subdivision or combination. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Subsequent Rights Offerings</U>. In addition to any adjustments
pursuant to <U>Section</U><U></U><U>&nbsp;9(a)</U> above, if at any time the Company grants, issues or sells any Common Stock or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any class of shares
of Common Stock (the &#147;<B>Purchase Rights</B>&#148;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the
number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the Maximum Percentage) immediately before the date on
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are to be
determined for the grant, issue or sale of such Purchase Rights (provided, however, to the extent that the Holder&#146;s right to participate in any such Purchase Right would result in the Holder exceeding the Maximum Percentage, then the Holder
shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance
for the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the Maximum Percentage). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)
<U>Pro Rata Distributions</U>. If the Company, at any time while this Warrant is outstanding, distributes to all holders of Common Stock for no consideration (i)&nbsp;evidences of its indebtedness, (ii)&nbsp;any security (other than a dividend,
distribution or adjustment covered by <U>Sections 9(a) or 9(b))</U> (iii) rights or warrants to subscribe for or purchase any security, or (iv)&nbsp;cash or any other asset (in each case, a &#147;<B>Distribution</B>&#148;), other than a
reclassification as to which <U>Section</U><U></U><U>&nbsp;9(d)</U> applies, then in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder
had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including without limitation, the ownership limitation set forth in
<U>Section</U><U></U><U>&nbsp;11(a)</U> hereof) immediately before the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined for the
participation in such Distribution (<I>provided, however</I>, to the extent that the Holder&#146;s right to participate in any such Distribution would result in the Holder exceeding the ownership limitation set forth in
<U>Section</U><U></U><U>&nbsp;11(a)</U> hereof, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership of any Common Stock as a result of such Distribution to such extent) and the
portion of such Distribution shall be held in abeyance for the benefit of the Holder until the earlier of (i)&nbsp;such time, if ever, as the delivery to such Holder of such portion would not result in the Holder exceeding the ownership limitation
set forth in <U>Section</U><U></U><U>&nbsp;11(a)</U> hereof and (ii)&nbsp;such time as the Holder has exercised this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)
<U>Fundamental Transactions</U>. If, at any time while this Warrant is outstanding (i)&nbsp;the Company effects any merger or consolidation of the Company with or into another Person, in which the Company is not the surviving entity and in which the
stockholders of the Company immediately prior to such merger or consolidation do not own, directly or indirectly, at least 50% of the voting power of the surviving entity immediately after such merger or consolidation, (ii)&nbsp;the Company effects
any sale, transfer or disposition to another Person of all or substantially all of its assets in one transaction or a series of related transactions, (iii)&nbsp;pursuant to any tender offer or exchange offer (whether by the Company or another
Person), holders of capital stock tender shares representing more than 50% of the voting power of the capital stock of the Company and the Company or such other Person, as applicable, accepts such tender for payment, (iv)&nbsp;the Company
consummates a stock purchase agreement or other business combination (including, without limitation, a reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with another Person whereby such
other Person acquires more than the 50% of the voting power of the capital stock of the Company (except for any such transaction in which the stockholders of the Company immediately prior to such transaction maintain, in substantially the same
proportions, the voting power of such Person immediately after the transaction) or (v)&nbsp;the Company effects any </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other
than as a result of a subdivision or combination of shares of Common Stock covered by <U>Section</U><U></U><U>&nbsp;9(a)</U> above) (in any such case, a &#147;<B>Fundamental Transaction</B>&#148;), then following such Fundamental Transaction the
Holder shall have the right to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately
prior to such Fundamental Transaction, the holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant without regard to any limitations on exercise contained herein (the &#147;<B>Alternate Consideration</B>&#148;).
The Company shall not effect any Fundamental Transaction in which the Company is not the surviving entity or the Alternate Consideration includes securities of another Person unless (i)&nbsp;the Alternate Consideration is solely cash and the Company
provides for the simultaneous &#147;cashless exercise&#148; of this Warrant pursuant to <U>Section</U><U></U><U>&nbsp;10</U> below or (ii)&nbsp;prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity
or other Person (including any purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the
other obligations under this Warrant. The provisions of this paragraph (d)&nbsp;shall similarly apply to subsequent transactions analogous of a Fundamental Transaction type. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Number of Warrant Shares</U>. Simultaneously with any adjustment to the Exercise Price pursuant to <U>Section</U><U></U><U>&nbsp;9</U>
(including any adjustment to the Exercise Price that would have been effected but for the final sentence in this paragraph (e)), the number of Warrant Shares that may be purchased upon exercise of this Warrant shall be increased or decreased
proportionately, so that after such adjustment the aggregate Exercise Price payable hereunder for the increased or decreased number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment.
Notwithstanding the foregoing, in no event may the Exercise Price be adjusted below the par value of the Common Stock then in effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f)
<U>Calculations</U>. All calculations under this <U>Section</U><U></U><U>&nbsp;9</U> shall be made to the nearest <FONT STYLE="white-space:nowrap">one-hundredth</FONT> of one cent or the nearest share, as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Notice of Adjustments</U>. Upon the occurrence of each adjustment pursuant to this <U>Section</U><U></U><U>&nbsp;9</U>, the Company at
its expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate setting forth such adjustment, including a statement of the adjusted
Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments and showing in detail the facts upon which such
adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Transfer Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Notice of Corporate Events</U>. If, while this Warrant is outstanding, the Company (i)&nbsp;declares a dividend or any other
distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any subsidiary,
(ii)&nbsp;authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii)&nbsp;authorizes the voluntary dissolution, liquidation or winding up of the affairs of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Company, then, except if such notice and the contents thereof shall be deemed to constitute material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company shall deliver
to the Holder a notice of such transaction at least ten (10)&nbsp;days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction;
<I>provided</I>, <I>however</I>, that the failure to deliver such notice or any defect therein shall not affect the validity of the corporate action required to be described in such notice. In addition, if while this Warrant is outstanding, the
Company authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction contemplated by <U>Section</U><U></U><U>&nbsp;9(d)</U>, other than a Fundamental Transaction under clause
(iii)&nbsp;of <U>Section</U><U></U><U>&nbsp;9(d)</U>, then, except if such notice and the contents thereof shall be deemed to constitute material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company shall deliver to the Holder
a notice of such Fundamental Transaction at least ten (10)&nbsp;days prior to the date such Fundamental Transaction is consummated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. <I>Payment of
Cashless Exercise Price</I>. Notwithstanding anything contained herein to the contrary, the Holder may, in its sole discretion, satisfy its obligation to pay the Exercise Price through a &#147;cashless exercise,&#148; in which event the Company
shall issue to the Holder the number of Warrant Shares in an exchange of securities effected pursuant to Section&nbsp;3(a)(9) of the Securities Act as determined as follows: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">X = Y <FONT STYLE="white-space:nowrap">[(A-B)/A]</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">where: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;X&#148; equals
the number of Warrant Shares to be issued to the Holder; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Y&#148; equals the total number of Warrant Shares with respect to which
this Warrant is then being exercised; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;A&#148; equals the Closing Sale Price per share of Common Stock as of the Trading Day on the
date immediately preceding the Exercise Date; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;B&#148; equals the Exercise Price per Warrant Share then in effect on the
Exercise Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of Rule 144, it is intended, understood and acknowledged that the Warrant Shares issued in such a &#147;cashless
exercise&#148; transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the Original Issue Date (<I>provided</I> that the Commission continues to take the
position that such treatment is proper at the time of such exercise). In the event that the Warrant Share Registration Statement or another registration statement registering the issuance of Warrant Shares is, for any reason, not effective at the
time of exercise of this Warrant, then this Warrant may only be exercised through a cashless exercise, as set forth in this <U>Section</U><U></U><U>&nbsp;10</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as otherwise set forth herein, in no event will the exercise of this Warrant be settled in cash. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. <I>Limitations on Exercise</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding anything to the contrary contained herein, the Company shall not effect any exercise of this Warrant, and the Holder shall
not be entitled to exercise this Warrant for a number of Warrant Shares in excess of that number of Warrant Shares which, upon giving effect or immediately prior to such exercise, would cause (i)&nbsp;the aggregate number of shares of Common Stock
beneficially owned by the Holder, its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Securities Exchange Act of 1934, as amended (the
&#147;<B>Exchange Act</B>&#148;), to exceed 9.99% (the &#147;<B>Maximum Percentage</B>&#148;) of the total number of issued and outstanding shares of Common Stock of the Company following such exercise, or (ii)&nbsp;the combined voting power of the
securities of the Company beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act to
exceed 9.99% of the combined voting power of all of the securities of the Company then outstanding following such exercise. For purposes of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the
number of outstanding shares of Common Stock as reflected in (x)&nbsp;the Company&#146;s most recent Form <FONT STYLE="white-space:nowrap">10-Q</FONT> or Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as the case may be, filed with the
Commission prior to the Exercise Date, (y)&nbsp;a more recent public announcement by the Company or (z)&nbsp;any other notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written
request of the Holder, the Company shall within two (2)&nbsp;Trading Days confirm in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock
shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder since the date as of which such number of outstanding shares of Common Stock was reported. By written notice to
the Company, the Holder may from time to time increase or decrease the Maximum Percentage to any other percentage not in excess of 19.99% specified in such notice; <I>provided</I> that any such increase or decrease will not be effective until the <FONT
STYLE="white-space:nowrap">sixty-first</FONT> (61st) day after such notice is delivered to the Company. For purposes of this <U>Section</U><U></U><U>&nbsp;11(a)</U>, the aggregate number of shares of Common Stock or voting securities beneficially
owned by the Holder and its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act shall include the shares of Common Stock
issuable upon the exercise of this Warrant with respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable upon (x)&nbsp;exercise of the remaining unexercised and <FONT
STYLE="white-space:nowrap">non-cancelled</FONT> portion of this Warrant by the Holder and (y)&nbsp;exercise or conversion of the unexercised, <FONT STYLE="white-space:nowrap">non-converted</FONT> or
<FONT STYLE="white-space:nowrap">non-cancelled</FONT> portion of any other securities of the Company that do not have voting power (including without limitation any securities of the Company which would entitle the holder thereof to acquire at any
time Common Stock, including without limitation any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive,
Common Stock), is subject to a limitation on conversion or exercise analogous to the limitation contained herein and is beneficially owned by the Holder or any of its Affiliates and other Persons whose beneficial ownership of Common Stock would be
aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act. For purposes of clarity, the Warrant Shares issuable pursuant to the terms of this Warrant in excess of the Maximum Percentage shall not be deemed to be
beneficially owned by the Holder for any purpose including for purposes of Section&nbsp;13(d) of the Exchange Act or Rule <FONT STYLE="white-space:nowrap">16a-1(a)(1)</FONT> promulgated under the Exchange Act. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) This <U>Section</U><U></U><U>&nbsp;11</U> shall not restrict the number of shares of
Common Stock which a Holder may receive or beneficially own in order to determine the amount of securities or other consideration that such Holder may receive in the event of a Fundamental Transaction as contemplated in
<U>Section</U><U></U><U>&nbsp;9(d)</U> of this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12. <I>Transfer Restrictions</I>. The Holder acknowledges that the Warrant Shares acquired upon
the exercise of this Warrant, if not registered pursuant to an effective registration statement under the Securities Act or eligible for resale without volume or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> restrictions or current public information requirements pursuant to Rule 144, will have restrictions upon resale imposed by state and federal securities
laws and such Warrant Shares will be imprinted with the following legend: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER
THE SECURITIES ACT OF 1933, AS AMENDED (THE &#147;SECURITIES ACT&#148;). THE HOLDER MAY NOT OFFER, SELL, TRANSFER, ASSIGN, PLEDGE, HYPOTHECATE, OR OTHERWISE DISPOSE OF OR ENCUMBER SUCH SECURITIES EXCEPT (I)&nbsp;PURSUANT TO AN EFFECTIVE REGISTRATION
STATEMENT OR PROSPECTUS UNDER THE SECURITIES ACT AND THE RULES AND REGULATIONS PROMULGATED THEREUNDER AND IN COMPLIANCE WITH ANY APPLICABLE STATE SECURITIES LAW, RESPECTIVELY, OR WITH AN EXEMPTION FROM SUCH REGISTRATION OR PROSPECTUS REQUIREMENT AND
(II)&nbsp;IN COMPLIANCE WITH THAT CERTAIN UNDERWRITING AGREEMENT, DATED DECEMBER&nbsp;20, 2023, AMONG THE ISSUER AND THE UNDERWRITERS PARTY THERETO. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13.
<I>No Fractional Shares</I>. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded
down to the next whole number and the Company shall pay the Holder in cash the fair market value (based on the Closing Sale Price) for any such fractional shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14. <I>Notices</I>. Any and all notices or other communications or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in
writing and shall be deemed given and effective on the earliest of (i)&nbsp;the date of transmission, if such notice or communication is delivered via facsimile or confirmed <FONT STYLE="white-space:nowrap">e-mail</FONT> prior to 5:30 P.M., New York
City time, on a Trading Day, (ii)&nbsp;the next Trading Day after the date of transmission, if such notice or communication is delivered via facsimile or confirmed <FONT STYLE="white-space:nowrap">e-mail</FONT> on a day that is not a Trading Day or
later than 5:30 P.M., New York City time, on any Trading Day, (iii)&nbsp;the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying next business day delivery, or (iv)&nbsp;upon actual
receipt by the Person to whom such notice is required to be given, if by hand delivery. The addresses, facsimile numbers and <FONT STYLE="white-space:nowrap">e-mail</FONT> addresses for such communications shall be: </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to the Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Annexon, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">1400 Sierra Point Parkway, Bldg. C, Suite 200 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Brisbane, California 94005 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Attention: Executive Vice President and Chief Financial Officer and Senior Vice President, Finance </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; text-indent:4%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail</FONT> addresses: <U>jlew@annexonbio.com</U> and <U>saleem@annexonbio.com</U> </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">If to the Holder, to its address, facsimile number or <FONT STYLE="white-space:nowrap">e-mail</FONT> address set forth herein or on the books
and records of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Or, in each of the above instances, to such other address, facsimile number or <FONT STYLE="white-space:nowrap">e-mail</FONT>
address as the recipient party has specified by written notice given to each other party at least five (5)&nbsp;days prior to the effectiveness of such change. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15. <I>Warrant Agent</I>. The Company shall initially serve as warrant agent under this Warrant. Upon ten (10)&nbsp;days&#146; notice to the Holder, the
Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation to which the Company or any new warrant agent shall be a party or any
corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this Warrant without any further act. Any such successor warrant
agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&#146;s last address as shown on the Warrant Register. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">16. <I>Miscellaneous</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>No Rights as
a Stockholder</U>. This Warrant does not entitle the Holder to any voting rights, dividends or other rights as a stockholder of the Company prior to the exercise hereof, except as expressly set forth in Section&nbsp;9. In addition, nothing contained
in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such liabilities are asserted by the Company or by
creditors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Authorized Shares</U>. Except and to the extent as waived or consented to by the Holder, the Company
shall not by any action, including, without limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution, issue or sale of securities or any other voluntary
action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such actions as may be necessary or
appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (a)&nbsp;not increase the par value of any Warrant Shares above the amount payable
therefor upon such exercise immediately prior to such increase in par value, (b)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid and
<FONT STYLE="white-space:nowrap">non-assessable</FONT> Warrant Shares upon the exercise of this Warrant, and (c)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body
having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant. Before taking any action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable
or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory body or bodies having jurisdiction thereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Successors and Assigns</U>. Subject to compliance with applicable securities laws,
this Warrant may be transferred or assigned by the Holder. This Warrant may not be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding on
and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal
or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Amendment and Waiver</U>. Except as otherwise provided herein, the provisions of the Warrants may be amended and the Company may take
any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Acceptance</U>. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions
contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Governing Law; Jurisdiction</U>. All questions concerning the construction, validity, enforcement and
interpretation of this Warrant shall be governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law thereof. Each party agrees that all legal proceedings
concerning the interpretations, enforcement and defense of the transactions contemplated by this Warrant (whether brought against a party hereto or their respective affiliates, directors, officers, shareholders, partners, members, employees or
agents) shall be commenced exclusively in the state and federal courts sitting in the City of New York. Each party hereby irrevocably submits to the exclusive jurisdiction of the state and federal courts sitting in the City of New York, Borough of
Manhattan for the adjudication of any dispute hereunder or in connection herewith or with any transaction contemplated hereby or discussed herein, and hereby irrevocably waives, and agrees not to assert in any suit, action or proceeding, any claim
that it is not personally subject to the jurisdiction of any such court, that such suit, action or proceeding is improper or is an inconvenient venue for such proceeding. Each party hereby irrevocably waives personal service of process and consents
to process being served in any such suit, action or proceeding by mailing a copy thereof via registered or certified mail or overnight delivery (with evidence of delivery) to such party at the address in effect for notices to it under this Warrant
and agrees that such service shall constitute good and sufficient service of process and notice thereof. Nothing contained herein shall be deemed to limit in any way any right to serve process in any other manner permitted by law. If either party
shall commence an action, suit or proceeding to enforce any provisions of this Warrant, the prevailing party in such action, suit or proceeding shall be reimbursed by the other party for their reasonable attorneys&#146; fees and other costs and
expenses incurred with the investigation, preparation and prosecution of such action or proceeding. Each of the Company and the Holder hereby waives all rights to a trial by jury. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Headings</U>. The headings herein are for convenience only, do not constitute a part
of this Warrant and shall not be deemed to limit or affect any of the provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Severability</U>. In case any one or more
of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the
Holder will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its
authorized officer as of the date first indicated above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><B>ANNEXON, INC.</B></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Name: Douglas Love, Esq.</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Title: President and Chief Executive Officer</TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><I>[Signature Page to <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant] </I></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF EXERCISE NOTICE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[To be executed by the Holder to purchase Warrant Shares under the Warrant] </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) The undersigned is the Holder of
Warrant No. ___________ (the &#147;<B>Warrant</B>&#148;) issued by Annexon, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the
Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) The undersigned hereby exercises its right to purchase Warrant Shares pursuant to the Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) The Holder intends that payment of the Exercise Price shall be made as (check one): </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Cash Exercise </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">&#9744;</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">&#147;<B>Cashless Exercise</B>&#148; under Section&nbsp;10 of the Warrant </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) If the Holder has elected a Cash Exercise, the Holder shall pay the sum of $__________ in immediately available funds to the Company in accordance with
the terms of the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5) Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in accordance with the
terms of the Warrant. Provided that the Warrant Shares are registered for resale on an effective Warrant Share Registration Statement or the Warrant Shares are eligible for resale without volume or <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> restrictions or current public information requirements pursuant to Rule 144, the Warrant Shares shall be delivered to the following DWAC Account Number: _______________________________________
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(6) By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in giving effect to the exercise evidenced
hereby the Holder, its Affiliates and any other Person whose beneficial ownership of Common Stock would be aggregated with the Holder&#146;s for purposes of Section&nbsp;13(d) of the Exchange Act will not beneficially own in excess of the number of
shares of Common Stock (as determined in accordance with Section&nbsp;13(d) of the Securities Exchange Act of 1934, as amended) permitted to be owned under Section&nbsp;11(a) of the Warrant to which this notice relates. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="64%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name of Holder:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&nbsp;</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Signature must conform in all respects to name of Holder as specified on the face of the Warrant) </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>4
<FILENAME>d456025dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt; margin-right:1%">


<IMG SRC="g456025g1215202845649.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Div Gupta </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">T: +1 212 479 6474
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">dgupta@cooley.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December&nbsp;21, 2023 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annexon, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1400 Sierra Point Parkway </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Bldg C, Suite 200 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brisbane, California 94005 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as counsel to Annexon,
Inc., a Delaware corporation (the &#147;<B><I>Company</I></B>&#148;), in connection with the offering by the Company of (i) up to 25,035,000 shares (the &#147;<B><I>Shares</I></B>&#148;) of the Company&#146;s common stock, par value $0.001 per share
(the &#147;<B><I>Common Stock</I></B>&#148;), and (ii) <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants (the &#147;<B><I>Warrants</I></B>&#148;) to purchase up to 18,379,861 (the &#147;<B><I>Warrant Shares</I></B>&#148;) shares of Common
Stock, pursuant to a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (No. <FONT STYLE="white-space:nowrap">333-258863)</FONT> (the &#147;<B><I>Registration Statement</I></B>&#148;), filed with the Securities and Exchange
Commission (the &#147;<B><I>Commission</I></B>&#148;) under the Securities Act of 1933, as amended (the &#147;<B><I>Securities</I></B> <B><I>Act</I></B>&#148;), the base prospectus included in the Registration Statement (the &#147;<B><I>Base
Prospectus</I></B>&#148;), and the prospectus supplement relating to the Shares filed with the Commission pursuant to Rule 424(b) under the Securities Act (together with the Base Prospectus, the &#147;<B><I>Prospectus</I></B>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In connection with this opinion, we have examined and relied upon the Registration Statement, the Prospectus, the form of the Warrants to be filed as an
exhibit to a Current Report of Form 8-K, the Company&#146;s certificate of incorporation and bylaws, each as currently in effect, and such other records, documents, certificates, memoranda and other instruments as in our judgment are necessary or
appropriate to enable us to render the opinion expressed below. We have assumed the genuineness of all signatures, the authenticity of all documents submitted to us as originals, the conformity to originals of all documents submitted to us as
copies, the accuracy, completeness and authenticity of certificates of public officials, and the due authorization, execution and delivery of all documents by all persons other than the Company where authorization, execution and delivery are
prerequisites to the effectiveness thereof. As to certain factual matters, we have relied upon a certificate of an officer of the Company and have not independently verified such matters. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With regard to our opinion regarding the Warrants and the Warrant Shares, we express no opinion to the extent that future issuance of securities of the
Company, anti-dilution adjustments of outstanding securities of the Company, or other matters cause the Warrants to be exercisable for more shares of Common Stock than the number available for issuance by the Company. Further, we have assumed that
the exercise price of the Warrants at the time of exercise is equal to or greater than the par value of the Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinion is expressed only
with respect to the General Corporation Law of the State of Delaware and, as to the Warrants constituting binding obligations of the Company, the laws of the State of New York. We express no opinion to the extent that any other laws are applicable
to the subject matter hereof and express no opinion and provide no assurance as to compliance with any federal or state securities law, rule or regulation. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">With regard to our opinion concerning the Warrants constituting binding obligations of the Company: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) Our opinion is subject to, and may be limited by, (a)&nbsp;applicable bankruptcy, reorganization, insolvency, moratorium, fraudulent
conveyance, debtor and creditor, and similar laws which relate to or affect creditors&#146; rights generally, and (b)&nbsp;general principles of equity (including, without limitation, concepts of materiality, reasonableness, good faith and fair
dealing) regardless of whether considered in a proceeding in equity or at law; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cooley LLP 55 Hudson
Yards New York, NY 10001-2157 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">t: (212) 479-6000 f: (212) 479-6275 cooley.com </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g456025g1215202845649.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annexon, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December&nbsp;21, 2023 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page Two </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(ii) Our opinion is subject to the qualification that (a)&nbsp;the enforceability of
provisions for indemnification or limitations on liability may be limited by applicable law and by public policy considerations, and (b)&nbsp;the availability of specific performance, an injunction or other equitable remedies is subject to the
discretion of the court before which the request is brought; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iii) We express no opinion with respect to any provision of the Warrants
that: (a)&nbsp;relates to the subject matter jurisdiction of any federal court of the United States of America or any federal appellate court to adjudicate any controversy related to the Warrants; (b)&nbsp;specifies provisions may be waived in
writing, to the extent that an oral agreement or implied agreement by trade practice or course of conduct has been created that modifies such provision; (c)&nbsp;contains a waiver of an inconvenient forum; (d)&nbsp;provides for liquidated damages,
default interest, late charges, monetary penalties, prepayment or make whole payments or other economic remedies; (e)&nbsp;relates to advance waivers of claims, defenses, rights granted by law, or notice, opportunity for hearing, evidentiary
requirements, statutes of limitations, trial by jury, service of process or procedural rights; (f)&nbsp;restricts <FONT STYLE="white-space:nowrap">non-written</FONT> modifications and waivers; (g)&nbsp;provides for the payment of legal and other
professional fees where such payment is contrary to law or public policy; (h)&nbsp;relates to exclusivity, election or accumulation of rights or remedies; or (i)&nbsp;provides that provisions of the Warrants are severable to the extent an essential
part of the agreed exchange is determined to be invalid and unenforceable; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(iv) We express no opinion as to whether a state court
outside of the State of New York or a federal court of the United States would give effect to the choice of New York law provided for in the Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On
the basis of the foregoing, and in reliance thereon, we are of the opinion that (i)&nbsp;the Shares, when sold in accordance with the Registration Statement and the Prospectus, will be validly issued, fully paid and nonassessable, (ii)&nbsp;the
Warrants, when duly executed by the Company and delivered to the purchasers thereof against payment therefor in accordance with the Registration Statement and the Prospectus, will be binding obligations of the Company, and (iii)&nbsp;the Warrant
Shares, when issued and paid for in accordance with the terms of the Warrants, will be validly issued, fully paid and nonassessable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinion is
limited to the matters stated herein and no opinion should be implied, or may be inferred, beyond the matters expressly stated. This opinion speaks only as to law and facts in effect or existing as of the date hereof, and we undertake no obligation
or responsibility to update or supplement this letter to reflect any facts or circumstances that may hereafter come to our attention or any changes in law that may hereafter occur. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cooley LLP 55 Hudson
Yards New York, NY 10001-2157 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">t: (212) 479-6000 f: (212) 479-6275 cooley.com </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g456025g1215202845649.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annexon, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">December&nbsp;21, 2023 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page Three </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We consent to the reference to our firm under the heading &#147;Legal Matters&#148; in the Prospectus and to
the filing of this opinion as an exhibit to a Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> to be filed with the Commission for incorporation by reference in the Registration Statement. In giving such consent, we do not thereby
admit that we are in the category of persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations of the Commission thereunder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sincerely, </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cooley LLP </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Divakar Gupta</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top">Divakar Gupta</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Cooley LLP 55 Hudson
Yards New York, NY 10001-2157 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">t: (212) 479-6000 f: (212) 479-6275 cooley.com </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>d456025dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g456025g1215203402692.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Annexon Announces Pricing of $125.0&nbsp;Million Underwritten Public Offering of Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BRISBANE, Calif., December&nbsp;20, 2023</B> &#150;&#150; Annexon, Inc. (NASDAQ: ANNX), a clinical-stage biopharmaceutical company developing a new class
of complement medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced the pricing of an underwritten public offering of 25,035,000&nbsp;shares of its common stock and <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase 18,379,861&nbsp;shares of common stock. The shares of common stock are being sold at a price of $2.880&nbsp;per share and the <FONT STYLE="white-space:nowrap">pre-funded</FONT>
warrants are being sold at a price of $2.879&nbsp;per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total gross proceeds to Annexon are expected to be approximately $125.0, before
deducting underwriting discounts and commissions and other offering expenses payable by Annexon. The offering is expected to close on December 26, 2023, subject to the satisfaction of customary closing conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Jefferies and TD Cowen are acting as joint book-running managers for the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The shares are being offered by Annexon pursuant to a shelf registration statement on Form <FONT STYLE="white-space:nowrap">S-3,</FONT> including a base
prospectus, that was filed with the Securities and Exchange Commission (SEC) and declared effective by the SEC on May&nbsp;3, 2022. The offering is being made only by means of a prospectus supplement and the accompanying prospectus that will form a
part of the registration statement. These documents can be accessed for free through the SEC&#146;s website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus, when available, may be obtained from: Jefferies
LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) <FONT STYLE="white-space:nowrap">547-6340,</FONT> or by email at Prospectus_Department@Jefferies.com; or Cowen and Company, LLC,
c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, Attn: Prospectus Department, by telephone at (833) 297-2926 or by email at PostSaleManualRequests@broadridge.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state
or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Annexon </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Annexon Biosciences (Nasdaq: ANNX) is a
clinical-stage biopharmaceutical company utilizing a distinct scientific approach to stop C1q and all inflammatory aspects of classical complement pathway activation before it starts. As the only company solely focused on shutting down the early
classical cascade, Annexon is developing a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">fit-for-purpose</FONT></FONT> pipeline of therapeutics designed to provide meaningful benefits across multiple diseases of the body, brain
and eye. With <FONT STYLE="white-space:nowrap">proof-of</FONT> concept data in both Guillain-Barr&eacute; syndrome and geographic atrophy, Annexon is rigorously advancing its <FONT STYLE="white-space:nowrap">mid-to</FONT> late-stage clinical trials
to bring their potential treatments to patients as quickly as possible. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This press release contains forward-looking statements within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, and Section&nbsp;21E
of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by terminology such as &#147;aim,&#148; &#147;anticipate,&#148; &#147;assume,&#148; &#147;believe,&#148; &#147;contemplate,&#148;
&#147;continue,&#148; &#147;could,&#148; &#147;design,&#148; &#147;due,&#148; &#147;estimate,&#148; &#147;expect,&#148; &#147;goal,&#148; &#147;intend,&#148; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g456025g1215203402692.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
&#147;may,&#148; &#147;objective,&#148; &#147;plan,&#148; &#147;positioned,&#148; &#147;potential,&#148; &#147;predict,&#148; &#147;seek,&#148; &#147;should,&#148; &#147;suggest,&#148;
&#147;target,&#148; &#147;on track,&#148; &#147;will,&#148; &#147;would&#148; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology. All
statements other than statements of historical facts contained in this press release are forward-looking statements. These forward-looking statements include, but are not limited to, statements about the expected gross proceeds from the offering and
the closing date of the offering. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated, including, but
not limited to, risks and uncertainties related to, among other things, market conditions and the satisfaction of customary closing conditions related to the public offering. Risks and uncertainties relating to Annexon and its business can be found
under the section titled &#147;Risk Factors&#148; contained in the preliminary prospectus supplement and the accompanying prospectus, the company&#146;s Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> and Quarterly Reports on Form
<FONT STYLE="white-space:nowrap">10-Q</FONT> and the company&#146;s other filings with the SEC. Any forward-looking statements that the company makes in this press release are made pursuant to the Private Securities Litigation Reform Act of 1995, as
amended, and speak only as of the date of this press release. Except as required by law, the company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investor Contact: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Monique Allaire </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">THRUST Strategic Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>monique@thrustsc.com </U></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media Contact: </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Sheryl Seapy </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Real Chemistry </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">949-903-4750</FONT></FONT> </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>sseapy@realchemistry.com </U></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>annx-20231220.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 12/22/2023 1:49:54 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2023"
  xmlns:annx="http://annexonbio.com/20231220"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://annexonbio.com/20231220"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" namespace="http://xbrl.sec.gov/dei/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2023/naics-2023.xsd" namespace="http://xbrl.sec.gov/naics/2023" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="annx-20231220_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="annx-20231220_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>annx-20231220_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 12/22/2023 1:49:54 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Three</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine3_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Three</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>annx-20231220_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20231012.2 -->
<!-- Creation date: 12/22/2023 1:49:54 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="annx-20231220.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressAddressLine3" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine3" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine3" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g456025g1215202845649.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g456025g1215202845649.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  L (@# 2(  A$! Q$!_\0
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M1SCW./I4>G?%.2.]%OKNF&V4GF2,,"GU4\D?0_A2]M"]KFBR;&N'/R?*ZO\
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-J/5^2Z%FBBBM3RC_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g456025g1215203402692.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g456025g1215203402692.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  V *4# 2(  A$! Q$!_\0
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MYNW;N8KTP<]*YC3C_P (=\1VM3\FG:H 4ST!;[OY-E?H:B\??\E&T3_=A_\
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5Z+-<.Z@CH<$T4478K(W:***0S__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.4</span><table class="report" border="0" cellspacing="2" id="idm140199690882464">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Dec. 20, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001528115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 20,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ANNEXON, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39402<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">27-5414423<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">1400 Sierra Point Parkway<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Bldg C<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine3', window );">Entity Address, Address Line Three</a></td>
<td class="text">Suite 200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Brisbane<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94005<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(650)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">822-5500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ANNX<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 3 such as an Office Park</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>d456025d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="annx-20231220.xsd" xlink:type="simple"/>
    <context id="duration_2023-12-20_to_2023-12-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001528115</identifier>
        </entity>
        <period>
            <startDate>2023-12-20</startDate>
            <endDate>2023-12-20</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2023-12-20_to_2023-12-20">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-12-20_to_2023-12-20"
      id="Hidden_dei_EntityCentralIndexKey">0001528115</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-12-20_to_2023-12-20">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-12-20_to_2023-12-20">2023-12-20</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2023-12-20_to_2023-12-20">ANNEXON, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-12-20_to_2023-12-20">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-12-20_to_2023-12-20">001-39402</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-12-20_to_2023-12-20">27-5414423</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-12-20_to_2023-12-20">1400 Sierra Point Parkway</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2023-12-20_to_2023-12-20">Bldg C</dei:EntityAddressAddressLine2>
    <dei:EntityAddressAddressLine3 contextRef="duration_2023-12-20_to_2023-12-20">Suite 200</dei:EntityAddressAddressLine3>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-12-20_to_2023-12-20">Brisbane</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-12-20_to_2023-12-20">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-12-20_to_2023-12-20">94005</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-12-20_to_2023-12-20">(650)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-12-20_to_2023-12-20">822-5500</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-12-20_to_2023-12-20">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-12-20_to_2023-12-20">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-12-20_to_2023-12-20">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-12-20_to_2023-12-20">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-12-20_to_2023-12-20">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-12-20_to_2023-12-20">ANNX</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-12-20_to_2023-12-20">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-12-20_to_2023-12-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M@6T ]]=2FK<3^Q&@^H8S^A]02P,$%     @ +X&55Y^@&_"Q @  X@P   T
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M':5_'<?VD-/IKV,BM'I;Z/EQ:%0*CMQC)8QQ8K3^-8+)#^Q^ %!+ P04
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MOS^QO-9.&G_FB^$_7G\!4$L! A0#%     @ +X&55P=!36*!    L0   !
M             ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4    "  O
M@9572[N"A^T    K @  $0              @ &O    9&]C4')O<',O8V]R
M92YX;6Q02P$"% ,4    "  O@957F5R<(Q &  "<)P  $P
M@ '+ 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( "^!E5?(E^0"
M=P0  ,\1   8              " @0P(  !X;"]W;W)K<VAE971S+W-H965T
M,2YX;6Q02P$"% ,4    "  O@957GZ ;\+$"  #B#   #0
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:+GAM;%!+!08     "0 ) #X"   9%      !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d456025d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>annx-20231220.xsd</File>
    <File>annx-20231220_lab.xml</File>
    <File>annx-20231220_pre.xml</File>
    <File doctype="8-K" isOnlyDei="true" original="d456025d8k.htm">d456025d8k.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d456025d8k.htm": {
   "nsprefix": "annx",
   "nsuri": "http://annexonbio.com/20231220",
   "dts": {
    "schema": {
     "local": [
      "annx-20231220.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd",
      "https://xbrl.sec.gov/naics/2023/naics-2023.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "annx-20231220_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "annx-20231220_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "d456025d8k.htm"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2023": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2023": 24
   },
   "report": {
    "R1": {
     "role": "http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2023-12-20_to_2023-12-20",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d456025d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2023-12-20_to_2023-12-20",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d456025d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "TradingSymbol",
     "presentation": [
      "http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "terseLabel": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CityAreaCode",
     "presentation": [
      "http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "Security12bTitle",
     "presentation": [
      "http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://annexonbio.com//20231220/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001193125-23-301190-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-301190-xbrl.zip
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MKZ^I/[Q"HKG9[#OP\5+>BE'T<+9##.O1: Z1;LIX'1,OY16 7*X7Y[<-F3O
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M>AFH=-)=+ 5C+-9D5B^VNQY^TAUTS/,OEK@^([= K?LK%!57K!=J/9];31J
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M!D(:W\(AYH1J"!%&AT3^D&'VW?& /::I52V+E10=[]S=7 )K%D&YQLRA8AW
M9>#TQ.6K%)XN^M;]Q&O58#+Y0H]+E;IM7Z^^Q2"<8#DTDHN+.H<(?7+QB7%2
ML2]@Z=:_<N5F1,NK2P_-U63 GU_:SN@8"J&!9 _M3>@2I7PMW<_)3E 0I0<U
M9FZUAKRR XFN]PCL#N.J[YXI=^U1*4EQOKD(].?98/C@E^IX?_#5\7ZUCO>M
M:VF[/"[J97$W&=2<['S!1OK):"C/UED_5P^R4SXG.]O4\H^62\=]Y[O)B\D.
M3,>/6]A5!KY'F.!8GI5PN4!I%EE@"]%5@2Q2*A7C%':W^.M.JKI92:97#.X
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MN84BA)"J."";5-,,Q2GC/YS@RPLDS"1OH25(3A7.V%OPE+A))CRJ 4Z-GK,
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M8!O; M3I3;L2;=P4Z\]DRM-M"-N$4OS9S<7IB^ZFNA1Y>2AI[)D3Q9P)G'/
MOL6+DFE54)^W'-1;!(3 #"M-6-4IT\ 2+Z5^<JA'_B?5W.-[?]+>!6_=O7D%
MO&.-A95,Y&*=FU 0RFS"2R;TWJWP(UJX(*/UG.C!S"F'HTZEU4,@'Q'L68I3
M6E7>KD15C)Y::++_AFR2["=KN)<Y[D[@ZI;&$[M9(]7SQ$+K!LOF!:Z>8PBU
M)'?7IXD4N0FS;J=#6I[>=FDJ3W^78 5%6N^__IBGIL'KP7U4W('0'4R%!)#
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MRUJBW^Z A/KX<8SX?J-W41F/LA=#=WHE8]Y. AM+<[A47A3W[&C!%]J%(S3
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MF)1/GBFMY#Q9Q1$PC!-]5+JIN81\9CUR3 RP<WY:\LHR!CD/X@8I[$BY! 9
M<OYOZE?&V.P.FEF9/FX#>E&-UYU>;A G/$2Z/F+QP0/ @%E.)8'^0O"R(S*=
M"7:>S,LZ;1HI2+&%'NY\!^:!+TCJTQ9DIJ:"LZQ#W]&YA$!4RW&,/F"O3X"M
MA2P>#J$\3RGAWS%[UY80'48>%=QKAPA>1)X-YZX?T+!EZ<#T(].,P'G!\%=\
MC?%0VZ&IC7? 4PT"X=4&#[^GM0P<^$KP_2O'ZSR0=^>S=4$I]NU[%@>WC(K
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MY=IY+KP_EQ$!RBKTLK1Q6%MLW5:<</=F^V/FO ;_K_:X,N2?<R7^X2\LJET
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MOBC:H--36P'.#5@8[1*P:R[%*(4CUNZI ^(PJBY <\\,X24Q?AQ7RU,_+2H
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M\ S;A)5U:WN>8N\VX0+0I$]M=6Y; #UOHJ-N%GS23S:HTW*25#G_9B>=G^_
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MS^>*;,C:8#AE%!OGPB,5E[)0Q<-,R]V*\H1T<][QA3JG9DK/Y@9HFQA1-<&
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M.31R(-,<;:1)'*3)%<;(=.3$?&HTN*)F:,,^I3,B4/:@MPAOH F&@"D()1=
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M">&L TJ(KC@X5U(M0<*@D!D2F@$;\X1E.>+1DPE&FU&ZR2(>8])BDY(5VN8
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M"1&@H.-H+$&@;3\7$X!5SY8.W4$<&4?MQ*HV*X>M5"''6D&\QP!7E&G#KDF
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MERY<@Y:\V83EE8WLA4<Q,K&J+=$L'+=,:M0U*H2":'9\6]43'9IPF]IH&]S
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MDMLA&^ZM=>EBD:1C*ZO83OWUVM%N<0WOZ!YB$!M:J(]7.OY!D(P*.WI./9L
MV"4@^5]=W-,*5J.WJDQ,A4N+=]]\CQ*2(]T<,BUU^G5;?HA*HQX6AW0P?NV:
M5"%DDL6TKFAR6IE>[.ZL2W-*/I2KAX#$1:G[BOYR6)1[<#1.5I] ,RF4?\*8
M"75+D5K*O67&JE\Z:9NB@L*(+'RT6?+NSK\/3Q9_ ,>K,Z=MN.5N\-):K;?6
M7"I%W)P2?!A@%'.'V(F4BN8%<<^K+2L?\O :5NY"-?/T.Y_E\5PJX"Y38[TP
M)?K78C?ZWJ0]$-XJQF^GNZIM!*C@B69[9E&Y0Q=YB=;"MD@LI#6IM"'#X4&?
MW.K--;LQ.+Q.# .J(EG!9*MSA+G6NHH3?N%_/S':.EY1#+4ID7D>N55-?35)
MX!:C5D/X4],ZL*8+!BZJYA92=H[BH$)IYJNKT-G]V[#KTES;^Y+"22.7<TFX
M3JM*Z**SY6XA)K\KD@9AH5OL5G9>-&Q=90BX31SV0DH<L2H4.UTOTR9>;(+[
MA1);;U4\H!%7J=RHM*C0MFD=F?QL$KF[\[5H9)7]8-@>%<]IL*S3$=9W4?1I
M@V>HJ!4%G+H:QB*.>]X(=&7]57V%#/Y_(L. M\@5L5EE^"5ZB#RX=;BG20I(
M1,L9'Y&* O=A_;U:1P\/?IA'OW0IT^$V8IZ5)"#54*C/4Y/HX'6Y46%ECN+.
M:9E.X3B^7DY8F=9V6,#D]%!/B\E-BRLK.\SXEFJF36S?T=K<JJAP(Z0VU_#1
MM;0\,O0- G >D?5;J^!]JQV7*=&O1"3CPBP:79C:TXAB'FMBS=9FJA1E7&=>
MK$J46EI.@]?-T"LO>@7Y)MP2W=<3UH;^==T=*9MA5N%6<MC&!P"4P <?9M.'
M.(>0545=W0YG@'.4%J*-*59PF-MYR8:$\3*3"DB"G#.N=*VD+29S9![$<0A.
MW.XJ1C2?6;=@=V<6W16F.F(EMD(2R>:+')W:$SM54EGRL"]V.ED7[_)+ Y;*
M5TC!/IX(#4^[P:#;N>KWAKWN(.AW+_O= 1+0D^"TV^\>OPM.V[]W@_.+87#<
M[9[# Z][ R"O\/O5^4FWO[OCC=#N#(.+5V@+?QP&;?C\I@O/G00M?(YMVN[3
M*KDYP =.+\Y@T.!-^QU->?'J5;<?PO!G9V$P[+?/!_2Y/1@ I0^#R[/NR>MN
M&)R^N[R MSOM(7RXZ ?XH?^V-^@&)[W!Y07\"RN"[[OGG:LWQS#^X*IS:B^Z
M^T>G>SD,6CU16BZO^H.K-F#J\")HGP==6$9GV ,X\/;[[6'OXAS5)Y@1]C?$
MP2_[%X-+>.QJP) ):@#3/C^AK_M79_@-?((!K\YHN &.\.;J['4;@8\[Z/(X
M^%CO/.A<O+D\Z[7/.UW@>L-3^/I=T+Z$KSKMXS.8"==BSW?6?AO"\+0F6/K9
M.P*-O H[[KZYQ&F#5S K \3>G+>C?O>_KGI]WBNL9W>GU5.PJEG:\+0]##K=
M_K -/](FWN*BSE\'[=?]+HT2!B>TSY-NIXM'PF,].@B#1P>/$'/>7,#C"*O>
M8' E4,"/>KAN'R#6[@_?,:R&%]^ Q#_>IXCI\RQX):T-@ [8;3OAEZGYI8D.
MZ- 4OXG2.H<B&3%-5]Z5/5%AI;FRNF#4*LM>L"E+UHYC,T7U,V0,V",3Q0.=
MG?BA1!UFIH?S:R%)UZ?(D=4E0H!)7Y2@6)"_CTO)^FR-.,\U;8CEVG.K]%3V
M_PTB* Z?$)/GG"DY\[94@A+Y+!F[8M%\ODREM$K!)DBR 2)S-=F^&^LRP1S:
ML<"S[YDC0K%(&=%-VRRC2EW#A*S%&B% 6;BH=A];]!W7KNZ%AO*,[LCB18!G
MW@9=&^=M$F$*'J7<*_L/VOSC+7I$Q@_1^&_4*G&P/'W^^""XW'^S']*IO,OR
M]R#N4E-QJC6(,J,=SN=73B.\M</]:IJ__2MLF/8QB5;:U$(I%&Z@8HYBA^XT
M5P.9P ,,X) /&ALV]N!&+K%!@RM4K<@*\5BQG9/4!TQNN4ZI?Q=6T4FI$,TX
M R&)[&KY+77.("O^"H>FP]!ERG"WJC2D5[271#+NF4'UBJBAN%@!)%N&;+#9
MW#>X>YDD=!%H^?#VC=5>=<72>329 !TI, 7$G",3N&*[WJ;N,>KQ3(U7CR"H
MJ_K\^S4+'/XP"WQ)LT!OZCF'UB8);*L4?-:2VB"E?$!JV$O':YEL$T"^Z&H.
MGQP<! .@*7D47&:@4 67($7<(44[GDVN]X,.: Q+N)H@2A[<^VJ/\Z0812F0
MX [@%.!S"DSB&6SAZ;TOK8V^7B1#SU&V&"])+O@=*><E4"W,UN8*!)V;))X&
MKY(T2LE4?8&]N47D&\0ILF;WK5 >CN]]BQOI=;>>7C]'H]R?L_CN?T>,^Z,D
MVP?2S17?D!%<':&%()[7/? %[NLGD@P=D)%Q 5?>3Y6;(7_]-%Y6"1@F65=*
M66?9>ZI&.Y%$5]_3]?55M(L\U(7S56XZ%N@C]Q6B9!'J $>I___E8(2E)1A(
M$D $4$@6U,4>,W175"W:A#&,*@$7+*AC.&"DU\=OZLS$*5[2UM/&S$0MX:?B
M<F&I@_P/WT)!>DH*DM(L*0[)6#]=Y3!)$RE]BL(A!;,HKV-T;5LD;2688Y(J
MZ9G2Z%<'KOCA22;G%RW1T6)!C","&?3.G93U.962S*7N_)J6=IF'R@"JSA35
M<M;E+NP!N4@E>:@P@(9_MDM/?]Q\IA>=X H_B16#S9P?-Z2J(ETTUX8V2=ME
MOBS(2$Q:N*J.*_)^801\:YVF^MVF ]?:<&3U-8_&<DS2GLX;#!VE!C"F0@_%
M+YM,X(2+,..[XFOP@)!Q32:*^VO!9:50'^FHAE^'P2(KR'])-7J2R9Y?[:6N
M^\$,;[%%)[!T3:HHJ-IU7\SXW^+&_D(W]DU28'0$UXHSL?KWT)3W/%.]G2)D
M)NS&8K3B/)FAC1^3+&;MV Z<4,&"'&$F<1JYM+?271:-E297\ZG*VF[14'5?
M7$+KMQR)=79-_ %+C1=$V*Q4(,?__,RK7H 944[Z]>Y.XF4CZ0M$R?3YDE.)
MR4>AZN[-DF@$.CJ[YE(/%G7]<?#!UOIB37:0QIYJ\;L&3%@NB*NWT_6TET1U
MK$"^RDOCQK>(T0B)%FCK"754_P*BPY=H->DW5Y>R2"J7RA1TDM8>1$> _TY4
M&?^87#Y(358^5_*SUBD"8L4E)Z2$[2;#(*8:4.4KI,E6W2D\)RP*,I-V3JG-
M#2A<6)+8*''.K?ENF@BH@J*AWY" .Q6$;IF@:L<VQU%L@JQTF2&XW[+/Z#9+
M)MPR,WY/-Y>^0"!E(V0FJG?=(L[)S2?Y@!)PTQA_PC%W9'K'<"5,9Z.#=LJR
MX2Z!WBK/]!A>)0L50ENB]*5</S6S3'4WZS)Z+V6D]#.Z?&BA)($T1AZ#^45H
MLZ/:($!)I#@8?"A58115BFJJ&4A=,J$N#G<=H5"+!"!"(R/*+F]M%%'F.^!F
MZ+"T*JY8U1J=.#2$$E!AIE <AVO%\#KU&?%YWU]-@K85*B!5+<EU3>U[V;GJ
M)"VL24#2D\/.]=PAL&)EM,2<5@_N#6 /;*B;$ <K:U;+AE2=9L8F_5E\37(/
M([;5H1A^W#+J$.]/02%P2I'RH+8QV)0SR5IC90PM)$LXEZ@-3GNEB"P0_@%5
MR).3C9"-6. 1,A9)6P&8;;XPGG2F4X612,6G#GB"92VQXOLHFZRPWQ<%O/\)
M][J8)+H:.;?,J8$]*C.\.">6,E/WV*L.4E_E]UB::?%M,^31B9PT78*P*HY5
MXR]=[_9"O%2RL5OMP(I?I"K,,I*;7U^7_; >^!*(J,!?*@'"/H>2.QZ&M3#=
M<$C$2K,)>9B:3^L[#D1[],/B_(5[5')/;=&CF,.U@25>JQ*W Q-@2RW[$E.]
MU*IN9K%[#(@)O?HA@L=*NLA%.Z9Y_+!.3\K'5R4\U'_>[BZ%K*\T^4KJ.OGI
M2B*I4[2PT1ZW#DOSUJ;%\I&41<1@+981I%X:V<;<)FI^"R&[/NA-G.0JN0"M
M/85[, R PCD48L^Z0(DJEFVTBBU4"1@%S4]*:5)=HDI=:&SMLE?,*XE,HL^M
MY')W'%..<5A,EE@'1^#:)<K\DNY5G%$9M52,P4H9JT<%=W6A9,<E>2,DOWU6
M^H1U"]S67-G9WZ+:D+OJA5VJ0>4X.<GI?O%[;4,H?-CY$1I4FQM$*&X?)@<B
M-ET8]289@40SX2!]D"9MGBTOJ*<]+ZL\Q>>28$X!G9J+^&@*93;)O477W]G[
M*[#?IG9=2.[X8/KB?EZ? L/WRRIZ%^EA6'B>6#4%I6FOH\7@$_ Z6P<*ZO[E
MY"3<2_USA,=K=NW#W3N+[EX$_\>2+$PU=$H2)9R$=8_E^?)&DQO1^50A2"RX
M"!@C:; D6V.<9 X4325R-!7GOZ;E,*H)S)1I!,-=>-A)4]5MF@4#B"A^4V7X
MEQ+NH.(HC.9M&KWPU0,-)5F(AHVQ'L (67^#\8R<U45COICQ\= E4 MW0$03
M;YOTLN23MB'F J*H@(HJ;J8FZ<LIG>V7E_0ZZZHF>V0), JELB-+TVU-/2V6
M%.G<%M4<$6@J7'3V#,)?MBTXI/%2^FL>4S %; .6E:UBL@R(P;;8L_F2U$'B
M1+F">T8)BZ[&XF*4"9IS$TYXEN<ZHO*J@W2.0MK,)2"'W&8HOU#)YGE2%L:@
M(S.[\K/*U__$183!<<:F%PS5?Q.E@ M &'2A*-1<)E8O+DK92@HJ+F\"QEA>
ML>('\2?58%/'$MI%K1Q<D,UGU"1RO"P*BZO@EFJ 0T:M(C2T2YH'96+1,QU\
MD>2;8M,&N3F,;3R+DCGU["JET!<.LR!Q@YU!KECCP]XTV4)PAU:J0?/,5$YL
M+I6M$'1(8,DFEH*T1PXZ^'<9FS =\^XFI&&XZ WH0"=8*@U2:&).FAV5&%8_
M<&HH>;\F3@?D-5L9K50<EJH]K]1O##^SXO]1W&*#('R@5'KDY#HP2[?AI0[;
M@6K^CNM6/^UI4XQV0I8F2LJJ(,=]Y3GTD5S/-8(=R\0V >2=JK@PGV->JW)O
MQ1*I2L(%#6IAJ[Q^BN">^[9T):C45%TC2YF"_5W$QE?=0XT=DVHN>8IE8LY4
MP'.?H^!"]!7(/A;,#^+$N&Z5;5=1-+)." /$8_:.E^PE1.%9PZ_V-G(:MP%G
MN!5LX#/2!>^:IS"AO7$R'RWSPDC0MLMY:A%^;6$"6I4!O]4.UVGLI#>.LX([
M,F =%.JF@5"C/(V)S79O43ZX%ELR=[A0":K8\2(K*!PE,RVKZZZ"W,SU&I7<
M6+FEN'&QLI+V5U(A8O@=J,SJ.[:(//YA$?D*S6E.8XJ(+93;$1DP?Z,S@W/F
M&9J1('%*L1F4)(K;*@#=*]"0:YJ\-"3 ,G%"(XDI.";H;A$&QY[W[1N(#+!8
M//OX5M(R).72.;3<E+PV6/M&ME[;L*VFZQ9I!_CN,A6*&'%RN?BL2!B5_KBJ
MHKPE],N*JL40C(*U<1U2BD2QAE$L!\'<E1TOK+XBD3$EWSQ:I%MUBAL*Y;#2
M\T A.4+>R/Z B+?D[F=F04Y5G# Q%4T^ 8K@8 Q4;AA>*/MB9%H2SW2I#!W;
M(<*('L',[UF4OGZ@@D_S_MGOOFGW*$/JXE5PV7[=#7I 7<XQ>ZE]=O8N..N^
M&@;'9^WS__SO[Y>P/_E!V+]H</4Y9JB==P>#X"UFC5V\<MTW:)4B&^7$)0?2
MB&(YH_PLD$V4<0LC5$R 0*8B8[4Q@5(G.' (K<-CTK[(45JAU]9&'AF,;$10
M&R$)TG(4)-[02;P<4F9@IWMV-KAL=WKGKW][</" /E^V3T[49SG/)WB<QQ=]
MN%#TM:R*OWD(.'#6OAQTGZL_U@+:/Q4\94;68?](_CA1$__CIP> U<,3\\/O
MLA7>K,$X]:#[_K-'ZGOX7]^:26W!0OJ$DM2?<VS!1V[!6QP<#,#R D%[CK?E
M"'OXGI]W_[@X#X$2=?:Q2J-9EKLD:VQKZ--N[_7I$#;ZB[M1ZWLSXZ,'C:-_
MO0T?':^>VROS3DJC9/4)>GOKFWZ(7XW(2V^^^D#-5B;!WP[HOX\MEVYNR[<'
MVV? [#R:Q\^#DVQY/0.R<I9AD]QN\=?^][6+(<;F/:]-+#"Y!Y)88-]E^ >)
MV!$SOZ\8.>YSWI>]HW\.@$U%)3KQ+J5@W<:0#]C@PU>4,.N%>Z ,TCL2(>D'
M)__LXSD^&G1.NR=7P. P >WXZ%O+G[""5Q?]-RA\=O_H]CM8;N#\8MCK=.]E
M.?\<9E*E7DLG#=&??OR1+OMA8>I7CCD^BR@Z!6G :UC_#+T9GU+ZXN/4U<,]
MTN&YFP0[CKFEB:[?-=W=4= YS_:#_V?^\VHRRU-V(6;)FP>X.^ERH&L%)_$L
MND-3@1V#Z0XH J@UX'[0X2Z3)%FRTKHT=GIE^+3\PY-X:AL[J;0)J[[:;S./
MHY3L%UY88:PW_O53=%J/JN<@5CH5 E=05)BVPC:AKE^ [)OIHD>MQWMV.1]N
M52)F[85NP543+>8U>P:.WAK?Q%B3,XWWJIF>9E&_?*1*8.3_+RK(VQJ"KTCX
MBH;-7I200HPH^"UH$E,>>,+]DY_J1 OY\2FP+4<<E[^9'?W];\_^\>2)\Y[]
M>Z-D&KA@#CX76UX$WL*P+YM!"U<B5?).K5[X P?^;7# $'Z_29]A <*:W;*%
M!UZ83P/^?%WJ]V0/O5RVEP6S7J2>>Q0X".Y4C7:KPA3+.>[F/RPVB[T$K8#P
M")U;7"]T2036R8RO">O@,FE6)H#'%;XJ8WNZ%USZW>B]JBU;=ZWT>9U5>;P^
MF 5V7KOK2Q4UUEAF+H]MM[%5X2U+W<)QV[9W:IADJR)RFU6L+8H7?\,J<C5[
MM;S,7KEO4U;EY&V[$[3A%#%/XIQ"TY_;\N:Z_Z3%]M?$Y%_VL!P\"F$Z3$!Y
M2&H1VI;E\ABSWPAD**/:7=6=%  * /$[TOC)=2HL8;*[(S*B'=BY137R?ZUB
MY%;9^6K=3;=,KLY7H ""NJK@K6@36?@B;6SVK!@'MH-S&=XZ[H3E<'T&9:4>
M<[ /BL%YC(%(-:&WGV$%_WY,WH^??J;-^Y<G]V;S/L*^)I-_7ROP=VN:1T.Q
MR1W\<4#_<@?T[^P[^6X/A=PK/X[E7^U8V%_T;W0NQI7U#9U8+>/!FF.1%LQ1
MR+CI%D5"LF&81//4X1Z!4ZA($I2GT3CVA+N]H-FC]?+GXXN3=_#EZ?#-V='_
M!U!+ P04    "  O@957_.=>@>@.  !W-@  $    &0T-38P,C5D97@U,2YH
M=&WM6VU3&SD2_DX5_T'EO6R1.ANP@4 ,<1UOFU#+ @7<YG+?Y!G95AAKYJ09
MP/OK[^F69CS8#DM>R.Z'I'83+(^D?GG4_71KV'MW_=MI;^_=\?Y1;WEI[_KD
M^O2X=_R?UM9J>V_-?\+P6OA>[!V<'WT0!V\/ST_/+]\TWK\[N3YNB*OK#Z?'
M;QJ)-JHU4GHXRKMGJ1W+I-$3RTN8?ZA,KFQO[^CD]_+A.QWGH^[.ZI8V#2$3
M/3180 WR!F]S43XVEG:H32M/L^YZEN^*\+F?YGDZ]D.#U.0MI_]0W?;T\T".
M=3+I7NNQ<N),W8G+="RQT_[IR=NS-PU+0C9Z>P>]X_N1[NM<0&&QMW;0VUN[
MZ-7VKRW>P>(SXLQ)T^C];/HNVZ55H/>GU%B@11ABP;KM%V0&-MW);V_%U>7A
MF\9P<^O5>F=KV.ZTMSKKG1U\W'R]^C$;DE+7;QJGYV_/O?$>:E#;FE7X6A/V
MCO2M>%MDN7QDIV_AJ]YU5_RS+3KMCMC<?BU>;6YO$A2?=<MX2(K]*TK31$U6
MHW3\_-94D1KWE?6XZ;2; L[=$(\ Z-OLNV^,ND]-4YR8:/6Y/=G>7%\75UI9
M*\5%JDTN+J2]N9.3Q_3\)CL?)/%0'#;%5:%S!=.N/[>J!U:[OC2J*0X1U0:I
M-5J*U]!_Z_E]>BICC1%I8O$6$3=18V6ZSX[@]TJ,Y*T2,LI5+*0345H8IQ*1
MIZ)$V?(2P:PII#A2B;R35N$IFZ56YCHU8B4?*?'S3^W-[5V$Y+V3WF$ZSJ29
M[*V=]"@HTU<[NR^;0AO,PYH13[O3^4C0U'0P4%:;H>A/^'.8CG&QHE^*(B-9
M.EO-]0W\#PRX$21P\]M>\?C,KK1*;5$:?;5+6H['D,'E:733%)FTXE8FA1+_
M6%]=7V^+3%F_S?+2(NUHZA5-G5.1O+>B(?7>+^=GUU6Z' &_+9?)2'5->F=E
MUNAE5K4&A8E5O+=&S_8$#&NER1=H]CY\,ZL;[)(5-AI)IX*9VCO-C>W7S9U7
M[4^N(A;;*5@5YO(*+B]=!>,4UA4T#\M+<:F&VN7!\U>YS FFN<"'7T :_ESM
MJ]9&J>_*6;KZYQ,V-C9:G:V=G5<;+ZN)LYHM%FK..0.= .,5[JY45%B=EX?N
M^!Z&-$.XG R@G?L4ML-WLP8D7]K9A?>CG$S:?KVQT:33)2$87+X O-6<<EWA
MO\ *<XK0Y#XY/;.IRW">"H?#%24%+8U31M]_PE%S&Q]@G>6EBVJAA9"F2;6]
M7)%EB5_/(B+D='B!#M;=PVC&U#6+UN%T621*;'8V5_J/F&\E3X<*XW:Z',DL
MIB)[@]25^J0ZJ\\?QT\613F-DY5IHREGWX60J^ZQ@J&H"PO#CAH_%EGZF/N\
MIK.:#^CDA3A7A@HR;U\%/Q#P<*!58,M\D \+:\F!EPJ!G$'*!WBG]6MS8<!4
M-M<#'4$0>A9HJV4 4J _06J 0$I&(\XC?OUD0H!4"/%1[K'D"CR0LD.MPBHQ
M)L5I5)!^^+&V$3Z-U1B;F%CR5#]+&QC&/TX;8?FTL.)C$0\9D92>8'WEG+1(
M(G9Y26; ;F8UR0[=E9%]X*Y@&UE5X2XX"'Y!;'8.=NNK)+U;%56.= [;^M,P
M5*: \PP>)'O()!$.99#,"ZN"6V2!OTVN(YU/RF<J16&&_ECGE'0A1<&:I*@?
MM)%)F \4D6=I-AZIOGS*4LM+$;2I!(G@#!E-FI3V<'!S+S99=%;&NO7I<U;T
M$QU1BL8C+%D9#N+":PBY_F 4P/7W.+D5(&(@^E;9!:HCS], DJQ+C0M>S1%\
M'Z3_.XP^=0O.U/":5?\KM-,D?(A''GEXBE6FG50Z6!7[_ !I*X&? =A/(1,<
M?5C1NND1K9]*.7L&("_;!<(_)!DL&\\W:0Y\QBHCE/%A@+A80H5C$#;\#E'I
M/<4AJX;2,DKHQ)1X]Z,<P^L!I'3T0]K M@DG!.I5BY3FOL_I#,*9N1@4=!@$
MXC[B?<0F<]/0[DW&R99L1L#*=2O627!O_+%PN<<+'DV+W.60B*2<6T14:Z0V
MH"D85D2R0*I8$!@!)!MIQY$ ITP@S*@Y#N1)WA2:IJ!B3\A;J9-J9J7?0_JZ
M*GXI+,DR1=,T?LA\><F;BZ6@Y*J]A1ZZ(.?/.9Q)WU5/(YL Z#+Q<4$,K0(D
M:T=HRF>G!JK4>:Q>_#98.Z^!BT2MXFEJDLGRTIV'(J>P$C>H>)2%0H>UK'(J
M[TKY.0'2AZH  1:84(7YE<D0-%VN\X(Y25][Q*0(8D->=!XR]($RU]Q6I-"'
MU-YP_'\:XKEJ8?SQBBPGF!(B!L "C_L9"-<?276/4>%#$A^W!;O0,++7K8XI
MFC"$+*/-Z\X!7?, FY4D&*B8;0ED.%:F=F @5U-8HETII=]AD;!9_MH !)\A
MB)JY"/29ONQ^D1(Y'-C2')Z[FR\^4RFJ3V?07GHW3WVN',L)Q9M$(T43I0#D
M5N1+WS":@@-TWMS8(LLI2P,/=BA-E?1 >-($&8R^(SJ4(R$68]0S5A8Q?&ER
MRO?F5DT("&!3JH]'>/?(JECC0Z!>$"*1 9THMJ*1Y^\J!!+)R;*:Y#SY$]S6
M=$1Y"%?)))2Y_:!%&*<89B(-?L&.H4P,3K'BZQ)XKLD(12#WM@BZL>\S'^3'
M%,7 ,C"/C"#!#L@VE+F;8IBF,1*U!SG_!&87*SQMAB\#L)+ QD =^!02@'!P
MK*^*)!VD2"F&$9%2+R'IG9-)=GU@I"9L]M36KZ@#9N=A"_GY&^$1=^8;*$JI
MXRE.3R_$UI9X5\2.ZO</L(BKPEA3G'T0[?7U]7:KT][:?N9.VJR$>5>L=-J=
ME]0,;KVB+L[@P4AG>TO,]FVY@[YV=/(["KAP!P'?\']PD,LGB7IXQ-5X3FX:
MRN10M?K TTVKKY"Q55<F=W+B&M!_+:. \>Y27)W\%U;8:)3K\AU)]Z?7_*<A
MWI\<7;][TX#]7E2Z'1Z?71]??N$MR6/W) LN)OZV]PGSG>CG; @_TF]_QJ[P
M!0 DKN_24KUO$AT^]Z+L*_/48XF*DRCQ25_<,+DA.E/E*>8Y5(Q&2O9UXFM%
M*KC 2QQG8B;"$&YLIFM@:!KI';4(P53"]+FL6"-*%(M#2Z&L/[,4?T^J>.Y7
MG$E#7.EZ9EZ**(ACDD!4:U(M[?,C6+(V'PL3E6)ZSL;Y@ 6P"C2=Z-*<F9!R
MM$-^]#,'H4X'T1<^M(2L2L-4BRJ7TQI]FQ9(H;M?<AJ_UN]P_&+^.DO#B3I6
M'ITM1:A<D13$2TAXWE#Q[QE.^Q%\T\4Z*LU4IZ7>7&']?QOV/Y-N3MW[8U"
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M_WL;!)JI%;^;!;_"?#/B3P& ?PCY/QCPWYX![ZW1KXYAD'_A[/]02P,$%
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M2P$"% ,4    "  O@95700\&^9@&  "Y20  %0              @ %L P
M86YN>"TR,#(S,3(R,%]L86(N>&UL4$L! A0#%     @ +X&55QJ>R#[0!
M_RT  !4              ( !-PH  &%N;G@M,C R,S$R,C!?<')E+GAM;%!+
M 0(4 Q0    ( "^!E5=6#$/?7!8  /Z'   .              "  3H/  !D
M-#4V,#(U9#AK+FAT;5!+ 0(4 Q0    ( "^!E5?.?*W)%I8  ! $ P 0
M          "  <(E  !D-#4V,#(U9&5X,3$N:'1M4$L! A0#%     @ +X&5
M5V?C TBO0@  ,RD! !               ( !!KP  &0T-38P,C5D97@T,2YH
M=&U02P$"% ,4    "  O@957_.=>@>@.  !W-@  $               @ 'C
M_@  9#0U-C R-61E>#4Q+FAT;5!+ 0(4 Q0    ( "^!E5<T:SMZ$PP  ,TC
M   1              "  ?D- 0!D-#4V,#(U9&5X.3DQ+FAT;5!+!08
.."  ( /H!   [&@$    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
